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Abbreviations and symbols 
μg   microgram 
μl    microliter 
AB   antibiotics 
ATP    adenosintriphosphate 
BAP   bacterial alkaline phosphatase 
BCCP   biotin carboxyl carrier protein 
BG   bacterial ghost 
bp    base pair 
cfu    colony forming units 
CM   cytoplasmic membrane 
CPS   cytoplasmic space 
CV   immunocontraceptive vaccine 
dH2O    distilled water 
DT   diphtheria toxoid 
E. coli   Escherichia coli 
FSH   follicle-stimulating hormone 
fwd   forewards 
g   gramm 
GnRH   gonadotropin-releasing hormone (=LHRH) 
hCG   human choriongonadotropin 
hCGß   human choriongonadotropin - subunit ß 
hCGß-LTB  human choriongonadotropin – ß fused to heat lab. enterotoxin B 
HRP   horst redish peroxidase 
hrs   hours 
HSD   heterospecies dimer 
IM   inner membrane 
IPTG    isopropyl-ß-D-thiogalactopyranosid 
Kb    kilobasepairs 
kDa    kilodaltons 
kg   kilogram 
l   liter broth 
LBv   Luria Bertoni vegetable 
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LH   luteinizing hormone 
LHRH   luteinizing hormone releasing hormone (= GnRH) 
LPS   lipopolysaccharide 
LTB   heat labile enterotoxin B 
MBP    maltose binding protein 
MCS    multiple cloning site 
min   minutes  
mg   miligram 
ml   mililiter 
ng   nanogram 
nm   nanometer 
OD600   optical density at 600 nm 
OM   outer membrane 
ON    overnight 
PBS    phosphate-buffered saline 
PCR   polymerase chain reaction 
pmol   picomol 
PP   periplasm 
PPS   periplasmic space 
rev   reverse 
rpm    rotation per minute 
RT    room temperature 
SD    Shine-Dalgarno sequence 
S-layer  surface layer 
sec   seconds 
strep   streptavidin 
TA   target antigen 
TFF   tangential flow filtration 
Tm   melting temperatur 
TSH   thyroid-stimulating hormone 
TT   tetenus toxoid 
V   volt 
WB   western blot 
ZP   zona pellucida
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GENES: 
 
 
 
 
Gentamycine 
 
gentamycin resistance 
gene 
 
 
 
Kanamycine 
 
kanamycine resistance 
gene 
 
 
 
Ampicilline 
 
ampicilline resistance 
gene 
 
 
 
Mobil. seq. 
 
gene encoding a mobility 
protein 
 
 
 
cI857 
thermosensitive allele of 
the phage λ-cI-repressor 
gene 
 
 
 
 
Eivb 
C-terminal fusion of the 
gene encoding the lysis 
protein E of the 
bacteriophage ΦX174 and 
the invivo- 
biotinylation sequence 
 
 
 
ara C 
 
arabinose operon 
regulatory gene of E.coli 
 
 
 
LacIq 
lacI gene under control of 
a mutated high 
expression lacI promoter 
 
 
 
GIII-MCS-myc-His 
GIII-targetsequence -
multipe cloning site – Myc 
– His – construct 
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hCGß-LTB 
human 
choriongonadotropin – ß 
fused to heat labile 
enterotoxin B 
 
 
 
MBP 
Gene encoding the 
maltose binding protein 
(MBP) 
 
PROMOTORS: 
 
  
PRM 
 
repressor maintenance 
promotor of 
bacteriophage λ 
  
Pmut 
 
mutated promoter of the 
PR promoter in 
bacteriophage λ 
  
PBAD 
 
promotor of the ara-
operon 
  
Ptac 
 
IPTG-inducible tac 
promotor 
  
PLacIq  
 
a mutated high 
expression lacI promotor 
 
ORIGINS OF REPLICATION: 
 
       
 
 
rep 
broad host range origin 
derived from the 
Bordetella bronchiseptica 
plasmid pBBR1 
  
PRM 
 
Pmut 
 
PBAD 
 
Ptac 
 
PLacIq 
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ori 
origin of replication 
 
 
 
 
phage f 
origin of the filamentous 
bacteriophage f1 
 
 
 
pBR322 
low copy replication and 
growth in E. coli  
 
 
 
M13 ori 
M13 intergenic region, 
origin of 
replication 
 
 
 
 
pMB1 
origin of high-copy 
number plasmids 
derived from pUC-vector 
series 
 
OTHER SYMBOLS: 
 
 
 
 
 
PCR 
 
 
polymerase chain reaction 
 
 
 
 
primers 
 
oligonucleotides for PCR 
 
               NcoI 
 
 
 
 
restriction site 
 
enzymatic DNA restriction 
at a certain site 
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1 Zusammenfassung-Summary 
1.1 Zusammenfassung 
1.1.1  Zielsetzung 
In den letzten Jahren beschäftigte sich das Team von Dr. Talwar (Talwar research 
foundation, New Delhi, India) mit der Herstellung von immunokontrazeptiven 
Vakzinen (Birth control vaccine) gegen das hCG (human chorion gonadotropin) 
Hormon, welches eine Schwangerschaft bei sexuell aktiven Frauen verhindern soll.  
HCG-ß (ß – Untereinheit des hCG) ist ein schwach immunogenes Hormon, welches 
von Trophoblastenzellen produziert wird. Es ist einerseits für die Implantation des 
Embryos in die Uterusschleimhaut und andererseits für die Aufrechterhaltung der 
Schwangerschaft in den ersten Wochen wichtig.  
HCG hat als einziger Impfstoff Phase I und Phase II der klinischen Studien an 
Menschen erreicht und zeigt sehr gute Ergebnisse. Als einziges Problem zeigte sich 
die geringe Effizienz (60 – 80%). Das bakterielle Ghost (BG)-System bietet sich 
hierbei als Lösung für dieses Problem an.  
BG‘s werden durch kontrollierte Expression des Lysegens E, aus dem 
Bakteriophagen ΦX174, aus Gram-negativen Bakterien gebildet. Das hierbei 
exprimierte Protein E führt zu der Bildung eines „Lysis- Tunnel“, der den 
periplasmatischen Raum verschließt und den Austoss des gesamten 
Zytoplasmainhalts ermöglicht. Zurück bleibt nur die intakte bakterielle Hülle.  
BG’s werden aufgrund ihrer Eigenschaften als Adjuvantien und/oder als Träger 
fremder, rekombinanter Proteine verwendet.  
Das Ziel dieser Arbeit war die Herstellung eines hCG-ß-LTB immunokontrazeptiven 
Impfstoffs auf Basis des BG-Systems. Die BG’s wurden mittels hCG-ß-LTB 
rekombinanten E. coli K12 produziert. Die hCG-ß-LTB Zielsequenzen wurde vor der 
Lyse-Induktion exprimiert und in den periplasmatischen Raum transportiert. 
1.1.2  Ergebnisse 
Die in einen pDrive Klonierungsplasmid eingebauten Zielsequenzen hCG-ß-LTB 
wurde von Dr. Talwar erhalten (Talwar Research Foundation, New Delhi, Indien).
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Durch Klonierung der hCG-ß-LTB Zielsequenz in die MCS (multiple cloning site) des 
pBGKA Vektors, wird ein neues Expressionsplasmid, pBGK-CGL, hergestellt.  
Das pBGKA Plasmid beinhaltet ein GIII-MCS-myc-6xHIS Genkonstrukt, das unter der 
Kontrolle eines L-Arabinose induzierbaren pBAD Promotors steht. Das GIII Gen 
kodiert die GIII-Signalsequenz, welche den Transport des fusionierten hCG-ß-LTB-
myc-HIS Proteins in den periplasmatischen Raum ermöglicht. Das Zielprotein wird im 
periplasmatischen Raum zurückgehalten.  
Die positiven pBGK-CGL Klone wurden zuerst mittels Anti-myc Antikörper bezüglich 
Proteinexpression getestet und danach mit dem Lysis Plasmid pGLysivb co-
transformiert. Die optimalen Expressions- und Lysisbedingungen wurden mittels 
einer „expression-lysis study“ ermittelt.  
Die rekombinanten BG’s wurden zuerst aus E. coli K12 NM522 gewonnen. Die 
Vorversuche zeigten zwar eine gute Proteinexpression, aber nach Lysis-induktion 
kam es zu einem Proteinabbau.  
Aus diesem Grund wurde die Produktion von rekombinanten BG’s aus E. coli K12 
W3110 getestet. 
Aus beiden bakteriellen Stämmen (E. coli K12 NM522 und E. coli K12 W3110) wurde 
jeweils ein Klon mit dem besten Expression-Lysis-Profil ausgewählt und für die 
Fermentation in einem 30Liter Fermenter verwendet. In den rekombinanten, 
lyophilisierten BG’s wurde die Konzentration an hCG-ß-LTB bestimmt. Die 
lyophilisierten BG’s wurden für weitere Fertilitäts-Versuche an Dr. Talwar (Talwar 
Research Foundation, New Delhi, India) verschickt und werden in Tierexperimenten 
an ihre anti-hCG Aktivität nach Immunizierung der Versuchstiere getestet.  
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1.2 Summary 
1.2.1  Objectives 
In recent years the team of Dr. Talwar (Talwar Research Foundation, New Delhi, 
India) was engaged with the production of immunocontraceptive vaccine (Birth 
control vaccine) against hCG (human chorionic gonadotropin) hormone with the aim 
to prevent pregnancy in sexually active women.  
hCG-ß (ß – subunit of hCG) is a weak immunogenic hormone which is produced by 
trophoblast cells. On the one side hCG-ß is important for the implantation of the 
embryo in the uterine lining and on the other side it is essential for the maintenance 
of pregnancy in the first few weeks.  
hCG is the only vaccine which has reached phase I and phase II of clinical trials in 
humans and showed very good results. The only one problem was its low efficiency 
(60 - 80%). The Bacterial Ghost (BG) system provides in this case an appropriate 
solution to this problem. 
BG's are formed by controlled expression of the lysis gene E from bacteriophage 
ΦX174, of Gram-negative bacteria. The expression of the E protein leads to the 
formation of a "Lysis tunnel" which closes the periplasmic space and allows the 
outflow of the entire cytoplasmic content. Only the intact bacterial envelopes remain.  
BG's are used due to its properties as adjuvants and/or as carriers of foreign 
recombinant proteins. 
The aim of this work was to produce an hCG-ß-LTB immunocontraceptive vaccine 
based on the BG system. The BG's were produced using hCG-ß-LTB recombinant E. 
coli K12. The hCG-ß-LTB target sequence was expressed and transported into the 
periplasmic space before the induction of lysis. 
1.2.2  Results 
The hCG-ß-LTB target sequence incorporated into pDrive cloning plasmid was 
constructed by Dr. Talwar (Talwar Research Foundation, New Delhi will, India). 
By cloning the hCG-ß-LTB target sequence in the MCS (multiple cloning site) of the 
pBGKA vector, a new expression plasmid, pBGK-CGL, was produced.
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The pBGKA plasmid contains a GIII-MCS-myc-6xHIS gene construct which is under 
control of an L-arabinose inducible pBAD promoter. The GIII gene encodes the GIII - 
signal sequence which facilitates the transport of the fused hCG-ß-LTB-myc-HIS 
protein into the periplasmic space. The target protein is retained in the periplasmic 
space. 
The positive pBGK-CGL clones were first tested for protein expression by using anti-
myc antibody and then co-transformed with the lysis plasmid pGLysivb. The optimal 
expression and lysis conditions were determined using an „expression-lysis study“. 
First, the recombinant BG's were produced from E. coli K12 NM522. The preliminary 
tests pointed to a good protein expression, but after lysis induction, there was protein 
degradation. 
For this reason, the production of recombinant BG's of E. coli K12 W3110 was tested. 
For both bacterial strains (E. coli K12 NM522 and E. coli K12 W3110), the clone with 
the best expression - lysis profile was selected and used for fermentation in a 30 litre 
fermenter. In the recombinant, lyophilized BG's the concentration of hCG-ß-LTB was 
determined. The lyophilized BG's were sent on Dr. Talwar (Talwar Research 
Foundation, New Delhi, India) for further fertility testing in experimental animals.  
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2 Introduction 
2.1 Immunocontraception 
Today's world is progressing very quickly. Because of the great buildup of knowledge 
over the past decades especially in scientific fields like medicine and natural sciences 
a continous increase in worldwide polpulation could be achieved, particularly in the 
developing countries like Africa, Asia and South America which causes more and 
more problems. Not only overpopulution but also the increase of the life-span cause 
economic as well as social problems. In the case of overpopulation issues for an 
effective, simple and inexpensive birth control are increasingly important.  
In recent years there have been used mainly mechanical and chemical birth control 
methods, such as - condoms, intrauterine devices, steroids in the form of pills, 
implants or injection depots. None of these methods are ideal, and without side 
effects. It is therefore an effort to find new methods for fertility control which should 
be fast, reliably reversible, high effective, free from systemic and metabolic side 
effects, inexpenssive, not disturb regularity menstruate or cause extra blood loss. 
Furthermore it should not block the ovulation or normal production of sexual 
hormones, it should be easily accessible, applicable at any age of reproductive live 
and be capable of privat use [1, 2, 8]. 
This new fertility control method is based on immunocontraception. 
Immunocontraception is a birth control method that uses the body's immune 
response to prevent pregnancy. Nowadays it is used  mainly to control populations of 
wild animals (e.g. elefants, white-tailed deer [5], Eastern Grey kangaroo [4], Brushtail 
possum [6]) and domestic animals e.g. cats [3], dogs [7], because it's more “humane” 
than killing and therefore more accepted in company and cheaper than castration.  
An immunocontraceptive vaccine (CV) for human must be more effective as a CV for 
animals. Therefore many scientific teams are working on this issue.  
Mammalian reproduction is exquisitely regulated by a cascade of hormones. Invasion 
of any of these hormones by competent antibodies will interupt fertility [1] (see Fig.1).  
First of all it’s important to find the correct hormonal pathway which shall be inhibited 
to avoid undesirable side effects.
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Fig. 1: Cascade of hormones regulating the reproductive system in mammals [1].  
 
2.1.1  Three main Categories of Contraceptive Vaccines [2] 
I. immunocontraceptive vaccines targeting gamete production  
- anti-luteinizing hormone / releasing hormone vaccine 
 
II. immunocontraceptive vaccines targeting gamete function  
- antisperm vaccine  
- antioocyte zona pellucida vaccine 
 
III. immunocontraceptive vaccines targeting gamete outcome  
-  anti-human chorion gonadotropin (hCG)-vaccine 
 
hCG hCG 
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I.  Anti-luteinizing hormone / releasing hormone (LHRH/GnRH) vaccine 
 
This vaccine is intended for both sexes - male and female. The target-homone 
structure is highly conserved in mammals, therefore the vaccine can be used in 
different species of animals (domestic pets, farm animals) [9].  
Anti-LHRH / GnRH vaccines will be used especially for control of fertility, libido and 
sex steroid production in companion animals - dogs, and animals raised for meat 
production - pigs, bulls [2, 9]. This type of vaccine is not suitable for use in humans 
because it stops the secretion of sex steroids [8, 9] (see Fig. 2).  
The anti-LHRH vaccine has also therapeutic applications in sex hormone-dependent 
cancers – e.g. breast, prostata. According to prostata cancer the anti-LHRH-vaccine 
reached phase II of clinical trials [1, 2, 9]. 
A recombinant vaccine based on the BG system carrying the multimeric LHRH or 
LTB-LHRH in sealed periplasmic space is currently under investigation [10].  
Fig. 2: Luteinizing hormone-releasing hormone (LHRH) is the key hormone regulating the 
formation of the gamets and sex steroids via pituitary and gonads. Application: Immunocontraception 
and immunosterilization in animal species; immunotherapy of prostatic hypertrophy [9].
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• bonnet monkeys [12] 
II-a.  Anti-oocyte zona pellucida vaccine  
 
Zona pellucida (ZP) is an extracellular layer between the egg cell (oocyte) and the 
follicular epithelium. It consists of glycoproteins, is homogeneous, glassy, serves as a 
mechanical protection and is equipped with sperm-specific receptors (i.e. only 
congener sperm can lead to fertilization) [12].  
Anti-oocyte zona pellucida vaccines are directed against key proteins of the zona 
pellucida. Main application potential of ZP-contraceptive vaccines is the control of 
wild animals and domestic animal populations. 
Research is going on for controlling animal populations such as: 
 
• white-tailed deer [2] 
• african elephant [2] 
• dogs [2] 
• possum in New Zeland [13, 14] 
 
All of these studies show good results but the main problem of the ZP-contraceptive 
vaccine is to find the right route of administration (delivery of the vaccine), to 
eliminate possible errors, to make the contraceptive vaccine safer, more effective and 
cheaper.  
A recombinant ZP vaccine based on the BG system, carrying different ZP proteins of 
brushtail possums, showed promising results. It is under investigation as a bite 
delivery vaccine in New Zeland [6, 13, 14]. 
 
Anti-sperm vaccines can be applied in both sexes.  
Some men are naturaly infertile because they produce antibodies against their own 
II-b.  Anti-sperm - vaccine 
 
At the surface of sperm there are a lot of different structures necessary for the 
binding of the sperm to the zona pelucida of the oocyte. If the zona pellucida proteins 
are occupied by antibodies, the sperm can not bind to the oocyte, anymore and 
therefore fertilization is not possible. Because of that all sperm-ZP binding site 
proteins are potential anti-sperm vaccine candidates [2].  
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sperm. In such cases an anti-sperm vaccine has a therapeutic effect. The removal of 
auto-antibodies leads to an increase in antibody-free sperms, improves the fertility 
and lead to normal pregnacies and healthy babies [11].  
 
2.1.2  Possible applications of hCG-ß  
III.  Anti – humanchoriongonadotropin - vaccine 
 
Human chorion gonadotropin (hCG) is a special glycoprotein hormone which is not 
formed constantly and not in all organisms. It is produced by normal trophoblast cells 
of the placenta during the early pregnancy – and its synthesis starts at the 
preimplantation stage [1]. It is essential for the implantation of the embryo into the 
uterus, as marmoset embryos exposed to anti-hCG antibodies failed to implant [1].  
hCG can be produced also during trophoblast diseases and by some kinds of tumors. 
Therefore hCG is also an important tumor marker [1, 2, 15]. 
hCG shows a heterodimeric structure with an α-subunit identical to luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH) 
and  an β-subunit unique to hCG consisting of 145 amino acids. The 
carboxyterminus (~37 amino acids) is unique and weakly immunogenic [1]. Therefore, 
it is a good candidate for development of a contraceptive vaccine. 
To improve the immunogenicity ß-hCG has to be modified either by haptens or by 
linkage to carriers (tetanus toxoid = TT, diphtheria toxoid = DT, heterospecies dimer 
= HSD) [1, 9]. 
• hCG is produced under normal conditions only in healthy pregnant 
women  
Why is hCGß a good candidate for developing of a contraceptive vaccine [1, 9]? 
 
• hCG can be synthetized by hCG synthetizing tumors  
• hCG provides the establishment of pregnancy and its maintenance in the 
early phase (first trimester) - (see Fig. 3) 
• hCG is a diagnostic marker of pregnancy, when hCG synthetizing tumors 
are excluded  
• hCG is inactivated by circulating anti-hCG antibodies  
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• Primary and secondary structures of hCG-ß are known, so they can be 
used for bioengineering  
• hCG is not involved in the hormone cascade for ovulation and not 
involved in the production of sex steroids which is a benefit (see Fig.1) 
 
Fig. 3: hCG synthesis and secretion during pregnancy. hCG is important for both establishment 
and maintenance of pregnancy [9]. 
 
The anti-hCG vaccine is the first and only CV which has successfully completed 
Phase I and II of clinical studies [2, 17].  
Studies showed that the vaccine is effective when the serum antibody titers go up ˃ 
50 ng/ml. To allow pregnancy again, the antibody titer should go down to ˂ 30 ng/ml 
[2, 16].  
During human clinical Phase I and II studies more than 200 women were examinated. 
The CV was free of side-effects, but generated protective antibody titers only in 60-80% 
of the examinated women. Since birth control vaccines have to be effective in 90-95% 
Application of hCGß-antigen for development of a birth control vaccine. 
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of the recipients in order to be accetable, further improvements are necessary for the 
usage of anti-hCG contraceptive vaccine [2, 16].  
The main task of the future is to enhance the immunogenicity of hCG by adding of 
new carriers or adjuvants. The Bacterial Ghost system (BG-system) can serve as 
both, a new carrier system of hCG as well as a potent adjuvant. The aim of this study 
is to combine the hCGß protein and the Bacterial Ghost system for development of 
an effective CV. 
 
• cervical carcinoma 
Application of hCG antibodies to combat tumors 
 
hCG is secreted not only by chorio carcinomas but also by many other tumor cell 
types [1, 2, 15]:  
 
• non-germ cell tumors of bladder, ovary, vulva, prostate, renal, pancreas, 
lung, colon, oral/facial tissue, stomach, breast.  
 
hCG acts on the tumor cells as an autocrine growth factor. It can be inactivated by 
anti-hCG antibodies followed by inhibition of tumor growth which leads to necrosis of 
the tumor [1]. 
 
 
Application of anti-hCG-antibodies as emergency contraception 
 
Today emergency contraception is called "day after pill" and consists of synthetic 
contraceptive steroids in high dose. The pill must be taken within 48-72 hrs after 
unprotected sex.  
Emergency contraception via anti-hCG antibodies is the method of the future. On this 
way many side effects can be minimized and the time period for intervention can be 
extended.  
The anti-hCG antibodies would be given within a week of the unprotected sex, to 
interrupt the implantation. The amount of antibodies requiered would be modest (eg. 
for a woman of 60 kg it would be around 250 µg) [1]. 
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2.2 Bacterial Ghost System 
Bacterial Ghosts (BG’s) are non living bacterial cells which consist of an intact 
envelope with all native surface structures but lack the whole interior of the cell 
(cytoplasm with all structures, DNA, ribosoms). BG’s are produced by expression of 
the cloned gene E from bacteriophage ΦX174 (E-mediated lysis) in Gram-negative 
bacteria [18, 19, 25] (see Fig. 4). 
2.2.1  E – mediated lysis 
Protein E, encoded by lysis gene E of bacteriophage ΦX174, is a very hydrophobic 
membrane protein of 91 amino acids [20] and can be divided into four domains in 
which the C- terminus is necessary for the oligomerization and the N- terminus has 
lytic activity [22, 23, 28] (see Fig. 5).  
The E-mediated lysis processes can be divided into three phases [22]. In phase 1 
Protein E integrates into the inner membrane by facing the C terminus to the 
cytoplasmic side (Fig. 5a). In phase 2, due to conformational change of protein E its 
C terminus is transfered across the inner membrane and assembles into multimers at 
the potential cell division sites [24]. In phase 3, the C-terminal domain of protein E is 
transfered towards the surface of the outer membrane of the bacterium. This leads to 
fusion of the inner and outer membranes and produces a lysis tunnel structure which 
is 40-200nm in size and localized in the potential zones of cell division (Fig. 5b). Thus, 
the membrane potential collapses and the whole interior of the cell bursts outwards 
[21, 22, 27] (Fig. 4). 
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Fig. 4: Bacterial ghost formation of protein E lysed Gram-negative bacteria [26]. Outburst of the 
inner cell mass through the E-specific lysis tunnel is showed in scanning electron micrograph. 
 
 
Fig. 5: E-mediated lysis process [23] 
Phase 1: protein E integrate into inner membrane (a); Phase 2: C-terminus of protein E is transferred 
across the inner membrane; Phase 3: C-terminus of protein E is transferred towards the outer 
membrane – production of lysis tunnel (b).  
Abbreviations: outer membrane (om), inner membrane (im), periplasm (pp).  
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2.2.2  Bacterial Ghosts as non-living candidate vaccine 
Because of its properties the BG system has a versatile use and can be used as a 
delivery system for proteins / antigens, nucleic acids, drugs and soluble compounds 
[35, 36, 37]. Due to its intact surface structures BG can be used as adjuvant and 
targeting vehicle. 
In this work, the BG system is used as carrier and adjuvant for foreign antigen, which 
is formed prior to lysis and anchored within the BG. 
 
What are the benefits of BG vaccines [35, 38, 39]? 
 
• BG’s can be generated from different Gram-negative bacteria 
• BG’s have native envelopes and no adjuvants are needed 
• BG’s have intrinsic adjuvant properties 
• A simultaneous presentation of multiple antigens (including foreign 
antigens) is possible 
• BG’s have a height capacity for foreign antigens 
• BG’s are very save – no host DNA, no live organisms, no horizontal 
gentransfer [40] 
• The endotoxicity of lipopolysaccharide (LPS) in BG’s is not a limiting 
factor for theirs application as vaccine [41] 
• The production is relatively cost-effective in comparison to the more 
expensive production of purified subunits, synthetic peptides, 
recombinant bacteria and viruses 
• BG’s can be stored by room temperature (RT) as freeze-dried material, 
therefore refrigeration is not needed 
• The intrinsic adjuvant properties of bacterial ghosts activate the innate 
immune system as well as the acquired immune response [47] 
• According to the identical surface receptors of BG’s with their living 
counterparts BG’s can be used for specific cellular and tissue targeting 
and thus also for tumor treatment [42] 
• The application is very easy – in addition to intramuscular vaccine can be 
administered oral, nasal, in the form of eye drops or rectal suppository 
[43].  
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BG posse a high capacity as carrier for foreign antigens, and can present several 
antigens simultanesly. The antigens can be incorporated at the following positions 
[35, 43, 34] (see Fig. 6):  
a. Outer membrane (OM) - the antigen is incorporated as a fusion protein of a 
known outer membrane structure (OmpA or Pilli). A good example is the 
hepatitis B antigen, which was expressed as an OmpA-fusion in E. coli [44]. 
b. Periplasmic space (PPS) - PPS of BG shows a closed structure and provides 
the antigen much more protection. Antigens are also immersed in a sugarrich 
environment of membrane-derived oligosaccharides which protects antigens 
during lyophilization [34]. The antigen is transported via different secretory 
systems into the PPS. To achieve this, the antigen is equipped with a specific 
PPS signalsequence (MalE-or GIII signal sequence). In this work, for 
periplasmic transport of hCG-ß-LTB antigen, the GIII secretory system was 
used. 
c. Inner membrane (IM) - the antigen is incorporated as a fusion protein with 
specific anchor sequences for attachment on the inside of the IM. For example, 
recombinants BG carrying HIV-1 reverse transcriptase [45]. Also DNA can be 
bound to the IM via membrane anchored DNA-binding proteins such as LacI 
repressors.  
d. Cytoplasmic space (CPS) - The CPS of BG can be filled either with water-
soluble subunit antigens or emulsions such that the target antigen itself or a 
matrix can be coupled to appropriate anchors on the inside of the IM of BG. 
For example, BG with streptavidin anchored on the inside of the IM can be 
filled by biotinylated target antigen (TA) [34, 46].  
e. S-layer (surface layer) - Expression of the cloned S-layer genes sbsA and 
sbsB of Bacillus thermophilus in E. coli leads to accumulation of sheet-like 
self-assembling SbsA or SbsB proteins in the cytoplasm. The S-layer self 
assembly products consist of several hundred thousand monomers per cell 
and they do not form inclusion bodies. Recombinant S-layer proteins rSbsA or 
rSbsB act as carriers of foreign antigens. When expression of S-layer sheets 
in E. coli is followed by E-mediated lysis, the S-layer structures are retained 
within the inner lumen of the cytoplasmic space of BG. Target antigens on 
rSbsA-, rSbsB- carriers can fill the inner lumen, be transported to the PPS or 
be anchored by membrane anchors on the outer surface of ghosts [48]. 
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Fig. 6: Schematic diagram of BG as carrier of target antigen (TA). TA can be localized in four 
different compartments of BG: 1. OM (outer membrane) as a fusion protein of OmpA; 2. PPS 
(periplasmic space) as maltosebinding protein or malE-sbsA/sbsB S-layer fusion proteins; 3. IM (inner 
membrane) anchored via E′, L′ or E′ and L′ anchor sequences; 4. CPS (cytoplasmic space) - TA on 
recombinant SbsA/SbsB- carriers can fill the inner lumen or membrane-anchored StrpA can bind any 
biotinylated TA to the IM. Adapted from [34].  
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2.2.3  Lysis plasmids 
Monitoring of E-lysis happens by measuring the optical density at 600 nm and by the 
determination of the live cell counts (i.e. colony forming units = cfu counts). As a 
result of the E-lysis there is a decrease in the OD600 and of the cfu. Protein E 
expression is also a demonstration for the E-lysis and therefore lysis plasmids carry 
the Eivb gene. The in vivo biotinylated protein E (Eivb) can be detected using 
streptavidin coupled to horseradish-peroxidase (Strep-HRP) [50]. 
Expression of lysis gene E, can be placed under transcriptional control of either the 
thermosensitive λpL/pR-cI857 or under chemical inducible promoter repressor 
systems, like lacPO-lacIq or the tol expression system. Several E-specific lysis 
plasmids with different resistance markers, origins of replication and gene E 
expression control systems have been published [29, 34].  
 
In different lysis plasmids the gene E expression is controlled by the rightward phage 
λpR promotor and the corresponding temperature-sensitive repressor, cI857, which is 
inactivated at temperatures higher than 30°C. Bacterial lysis is induced by a 
temperature shift of the growing culture from 28°C to 42°C [30, 31]. Mostly it is 
favorable to cultivate the bacteria at temperatures higher than 28°C. Therefore it was 
important to extend the heat stability of the λpR-cI857 promotor repressor system. A 
mutation in the OR2 operator region of the rightward λpR promotor increased the 
temperature stability of the λpR-cI857 gene expression system. Thus gene E 
expression is repressed at temperatures up to 36°C and cell lysis is induced at 38°C 
or higher [31]. 
 
pGLysivb lysis plasmid 
 
In this work lysis plasmid pGLysivb was used for production of BG’s carrying gene 
Eivb (in vivo biotinylated protein E) under control of the mutated heat inducible λpR-
cI857 promotor repressor system. Additionally pGLysivb contains a gentamycin 
resistance cassette and a mutated mobilization gene sequence with reduced 
mobilization activity [32] (see Fig. 7).  
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Fig. 7: Map of pGLysivb lysis plasmid [6201 bp]. Mob: mobilization gene; Gent: gentamycin 
resistance cassette; Eivb: protein E fused to in vivo biotinylation sequence, which is under control of 
the mutated heat inducible λpR-cI857 promotor repressor system. 
 
I. pGLysivb-2x lysis plasmid 
 New lysis plasmids 
 
Amongst others the task of this work was the design and testing of three new lysis 
plasmids (pGLysivb-2x, pGLMivb, pGULMivb).  
 
 
pGLysivb-2x is a pGLysivb derived lysis vector with a second E-specific lysis 
cassette which is under control of the mutated λpR-cI857 promotor repressor system 
(see chapter 4.2.1.). 
 
II. pGLMivb lysis plasmid 
 
pGLMivb is a pGLysivb derived lysis vector with an E-specific lysis cassette which is 
controlled by chemical inducible LacIq repressor / Ptac promoter system (lysis-
induction with IPTG) (see chapter 4.2.2.). 
 
III. pGULMivb lysis plasmid 
 
pGULMivb is a pGLysivb derived lysis vector with E-specific lysis cassette which is 
controlled by the chemical inducible LacIq repressor / Ptac promoter system (lysis-
induction with IPTG). 
This lysis plasmid was designed for Neisseia species and therefore it includes a 
10bp-Uptake-sequence (5’- GCCGTCTGAA- 3’) (see chapter 4.2.3.). 
Neisseria species are known to be transformed less readily if transforming DNA 
competes with DNA containing the 10-bp sequence GCCGTCTGAA. It has been 
Mob   Gent    c1857 
PRM   Pmut 
 
Eivb 
rep 
ori 
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postulated that the 10-bp sequence is a recognition sequence which is required for 
efficient DNA uptake [33]. 
2.2.4  Expression plasmid pBGKA 
Plasmid pBGKA is derived from plasmid pBAD/GIII/A (Invitrogen) by replacement of 
the ampicillin resistance cassette through the kanamycin resistance cassette from 
plasmid pBHR1 [14]. 
 
 pBAD/gIII system  
 
pBAD/gIII plasmids are expression vectors that provide regulated expression of 
recombinant protein and purification in E. coli. 
pBAD/gIII allows the secretion of  expressed proteins  into the periplasmic space 
where oxidative conditions favor the formation of structural disulfide bonds for the 
production of functional proteins. Periplasmic secretion also separates the 
recombinant protein from cytosolic proteases. The leader peptide for secreted 
expression into the periplasm originates from the bacteriophage fd gene III (gIII) 
protein. pBAD/gIII vectors contain also a C-terminal c-myc epitope for detection and 
analysis by  Anti-myc antibodies, a C-terminal 6xHis Tag for rapid purification and 
detection with Anti-His (C-term) antibodies and an araBAD promoter for a tightly 
regulated expression [49] (see Fig. 8).  
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Fig. 8: pBAD/gIII periplasmic expression system, Invitrogen [49].  
 
• araBAD promotor for dose-dependent regulation  
araBAD promoter system 
 
The araBAD promotor system allows tightly regulated expression as well as a dose-
dependent induction and high protein yields. 
The following features are included in all pBAD vectors: 
 
• araC gene for tight control of the araBAD promotor 
• optimized ribosome binding site for increased translation efficiency 
• rrnB transcription termination region for efficient transcript processing 
 
The araBAD promotor is positively and negatively regulated by the product of the 
araC gene, a transciptional regulator. In the absence of arabinose, the AraC dimer 
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binds to the DNA and represses the expression by the formation of a 210 bp DNA 
loop. If arabinose is available it binds to AraC and releases the DNA loop which 
therefore allows the transcription to begin (see Fig. 9). Very low uninduced levels of 
transcription from the araBAD promotor are repressed by glucose. Glucose acts 
through lowering cAMP levels causing cAMP activator protein binding to the CAP site 
on the DNA and therefore lowering the stimulation of transcription [49]. 
 
Fig. 9: Regulation of the araBAD promotor. No transcription – AraC dimer binds to the DNA and 
leads to formation of a 210 bp DNA-loop. Transcription – L-arabinose binds to AraC and releases the 
DNA loop [49].  
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3 Materials and methods 
3.1 Bacterial strains, plasmids, media, antibiotics, 
cultivation 
3.1.1  Bacterial strains 
• Escherichia coli K12 NM522 sup E thi-1Δ(Lac-proAB)Δ(mcrB-hsdSM) 
5(rK-mK-) (F’proABlacIqZΔM15) (Source: Stratagene, 
Heidelberg,Germany) 
• Escherichia coli K12 C2988J (NEB 5-alpha competent E.coli)  fhuA2 
Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 (Source: New England Biolabs, Germany) 
• Escherichia coli K12 W3110 lonˉ lambdaˉ Fˉ mcrA mcrB IN(rrnD – rrnE) 1; 
(Source: Lab. Stock)  
3.1.2  Plasmids 
• Backbone plasmids 
Name Size Resistance Origin Reference Features 
pBGKA 
 
4040 bp 
 
Kanamycin 
 
pBR322 
 
[14] 
 
 PBAD  / 
gIII-myc 
pDRIVE-hCG-
ß-LTB 
4530 bp Kanamycin 
/ Ampicillin 
pMB1  [51] hCGß-LTB 
/ Plac 
pMal-p2X 6721 bp Ampicillin pMB1 NewEngland 
Biolabs Inc. 
LacIq /  
Ptac 
• Expression plasmids 
Name Size Resistance Origin Ref. Features 
pBGK-CGL 
 
4763 bp 
 
Kanamycin 
 
pBR322 
 
this work 
 
gIII-hCGß-
LTB-myc / 
PBAD 
pBAD/GIII/calmodulin 
 
4556 bp 
 
Ampicillin 
 
pBR322 
 
Invitrogen 
 
PBAD / gIII-
calmodulin 
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• Lysis plasmids 
Name Size Resistance Origin Reference Features 
pGLysivb 6201 bp Gentamycin Rep [32] λPRmut/Eivb 
pGLysivb-2x 7168 bp Gentamycin Rep  this work λPRmut / 
Eivb-Eivb 
pGLMivb 6680 bp Gentamycin Rep  this work LacIq / 
Eivb 
pGULMivb 6696 bp Gentamycin Rep this work Uptake seq 
/ LacIq / 
Eivb 
3.1.3  Cultivation media 
• Low salt LBv-Medium - 10g/L Peptone of Soya, 5g/L yeast extract and 
5g/L NaCl, adjusted to a pH of 7.4. 
• Plate - Count agar - plates for determination of the cfu – 23,5 g/L  
• Low salt LB-Agar - 10g/L Peptone, 5g/L yeast extract and 5g/L NaCl, 
adjusted to a pH of 7.4. For agar plates 15 g agar/L is added to the media.  
 
All media are autoclaved for 30 minutes at 121°C. All chemicals are purchased from 
Carl ROTH (Karlsruhe, Germany).  
3.1.4  Antibiotics 
Name Stockconc. [mg/ml] Endconc. [µg/ml] µl / 5ml 
Ampicillin 50 100 10 
Kanamycin 25 50 10 
Gentamycin 10 20 10 
Tetracyclin 5 10 10 
Streptomycin 20 100 25 
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3.1.5  Cultivation of Escherichia coli 
Bacterial cultures are incubated in 5 ml LBv-medium in standard epprouvettes. For 
specific plasmids the corresponding antibiotics and/or additional glucose have to be 
added. The incubation is carried out at 36 ° C in a rotating incubator wheel (Heraeus 
BK5060E). The plates are incubated in a temperature regulating incubator at 28 ° C 
or 36 ° C (Heraeus BK5060E). 
3.2  Buffers and solutions 
50% Glycerin 
   25 ml 100% glycerin  
   25 ml dH2O 
   mix well and sterilize by autoclaving 
 
Agarose gel – 1% or 2% 
   weigh out 3 g or 6 g agarose 
   dissolve in 300 ml 1xTAE 
   melt in microwave and cool down with stirring to hand-hot 
   pour into electrophorese tray 
 
0,85% Saline Medium 
   8,5 g NaCl 
   fill up with dH2O to 1 liter 
   fill into epprouvettes 9 ml or 9,9 ml using dispenser 
   autoclave 
 
GelRed staining solution 
   GelRedTM nucleic acid gel stain, 10000X in water (No. 41003) is 
   ordered from Biotium and stored at RT protected from light. 
   15 µl GelRed stain 
   5 ml 1M NaCl 
   45 ml dH2O 
   keep the staining solution protected from light 
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MOPS I 
   10,47 g MOPS (100mM) 
   0,74 g CaCl2 x 2 H2O (10mM) 
   0,6 g RbCl2 (10mM) 
   dissolve in 400 ml dH2O 
   adjust pH to 7,0 with KOH 
   fill up to 500 ml and autoclave 
  
MOPS II 
   10,47 g MOPS (100mM) 
   5,15 g CaCl2 x 2 H2O (70 mM) 
   0,6 g RbCl2 (10mM) 
   dissolve in 400 ml dH2O 
   adjust pH to 6,5 with KOH 
   fill up to 500 ml and autoclave 
  
PonceauS 
   0,2 g PonceauS 
   3,0 g Trichloric acetic acid 
   fill up to 100 ml dH2O 
   it is reuseable 
 
1xNuPage® Sample Buffer 
   6,5 ml PBS 
   2,5 ml NuPage® LDS Sample Buffer (4x) 
   1 ml NuPage® Reducing Agent (10x) 
 
10x PBS  137 mM NaCl 
   2.7 mM KCl 
   10 mM Na2HPO4 
   2 mM KH2PO4 
   800 mL dH2O 
   pH 7,4 with HCl 
   fill up to 1 L with dH2O 
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50% Glucose - Dissolve Glucose Anhydrat = 50 g Glucose in 70 ml dH2O and 
   fill up to 100 ml  
   or 
     - dissolve Glucose Monohydrat = 55 g Glucose in 70 ml dH2O 
   and fill up to 100 ml  
   Filter sterilize or autoclave  
3.3  Chemicals 
Buffers, chemicals, media and solutions are purchased from:  
 
   Carl ROTH (Karlsruhe, Germany) 
   Merck (Darmstadt, Germany) 
 
Materials for SDS-PAGE, Western blot and protein quantification are purchased from: 
 
   Invitrogen (Paisley, UK) 
   Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
    Carl Roth (Karlsruhe, Germany) 
 
The markers are purchased from: 
 
   Fermentas Life Sciences (St. Leon-Rot, Germany) 
3.4  Enzymes 
Restriction and ligation enzymes are purchased from: 
 
   Fermentas Life Sciences (St. Leon-Rot, Germany) 
   New England Biolabs (Frankfurt a. Main, Germany) 
   Promega (Mannheim, Germany) 
 
All reactions are performed according to the manufacturer’s instructions. 
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3.5  Microbiological, molecularbiological and biochemical 
methods 
3.5.1  Preservation of bacterial strains  
   Add 900 µl 50% sterile glycerins to the labeled cryo-tubes 
   Add 900 µl bacterial cultures 
   Mix by shaking  
   Stored by – 80°C 
3.5.2  CaCl2 / RbCl2 competent cells 
30 ml of sterile LBv-medium is inoculated with 1 ml over night bacterial culture. The 
culture is incubated under continuous shaking at 36°C till an OD600 of ~ 0,5 is 
reached. The culture is centrifuged for 10 minutes at 4 ° C and 4000 rpm. Thereafter, 
the supernatant is decanted, the pellet resuspended in 6 ml MOPS I and placed on 
ice for 10 minutes. The cells are again centrifuged for 10 minutes at 4 ° C and 4000 
rpm. The supernatant is decanted and the pellet resuspended in 6 ml MOPS II and 
placed on ice for 30 minutes. The cells are centrifuged for 10 minutes at 4 ° C and 
4000 rpm. The supernatant is decanted and the pellet is resuspended in 480 μl 
MOPS II and 180 μl of 50% glycerol and placed on ice for 10 minutes. Aliquots are 
made in 100 μl portions and frozen at -80 ° C. 
 
The competent cells are checked by single cell strikes on LBv plates and by 
microscopy. 
3.5.3  Transformation of CaCl2 / RbCl2 competent cells 
The DNA (2 μl of Miniprep or 10-20 μl of ligation) is pipeted into the 100 μl aliquot of 
competent cells and placed for 30 minutes on ice. After that, a heat shock at 36 ° C 
or 42 ° C is performed for 2 minutes (depending of the plasmid used). The cells are 
placed for 5 minutes on ice. After addition of 700 μl LBv-medium, the cells are 
incubated on the shaker at 36 ° C. After the regeneration, the transformed cells are 
plated on agar plates with the coresponding antibiotics (100 μl and the remaining 
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rest). The agar plates are incubated over night at 36 ° C. Bacteria that have 
incorporated the plasmid can grow on the antibiotic-plates. 
3.5.4  Preparation of plasmid DNA - Miniprep  
The PeqLab Miniprep Kit I (PeqLab, Erlangen, Germany) is used according to the 
manufacturer’s instructions. This PeqLab Miniprep Kit I is meant for 1-5 ml over night 
culture. 
3.5.5  Preparation of plasmid DNA – Midiprep 
• The PeqLab Midiprep Kit II (PeqLab, Erlangen, Germany) is used 
according to the manufacturer’s instructions. This PeqLab Midiprep Kit II 
is meant for 50 ml over night culture. 
• The Promega Midiprep Kit (Promega, Mannheim, Germany) is used 
according to the manufacturer’s instructions. This Promega Midiprep Kit 
is meant for 100 ml over night culture. 
3.5.6  Enzymatic reactions 
3.5.6.1  Sequence specific cleavage of DNA 
All restrictions digests are prepared according to the manufacturer’s instructions. 
3.5.6.2  Ligation 
Ligation reactions are performed with T4 DNA Ligase and T4 ligase buffer (from New 
England Biolabs, Frankfurt a. Main, Germany) overnight at 4°C.  
 
Ligation-mix  6 µl Insert 
   3 µl Vector 
   2 µl 10mM ATP 
   2 µl T4 DNA ligase buffer (10x) 
   1 µl T4 DNA ligase (5 u/µl) 
   6 µl dd H2O 
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3.5.7  Electrophoresis 
DNA fragments are separated on 1% and 2% agarose gels (Maniatis et al., 1982) 
with 140 – 160 V and 1xTAE as running buffer. To determine the size of the 
fragments also a DNA marker is loaded (Fermentas GeneRuler™ 1kb marker, 50 bp 
marker). GelRed staining of the gel and observation under UV-light (250 nm) makes 
the DNA fragments visible. Gels are documented using Quantity One software 
(BioRad, Hercules, CA, USA). 
3.5.8  Isolation and purification of DNA fragments 
Isolations and purifications are performed with 
• Clean and Concentrator Kit (GeneXpress, Wiener Neudorf, Austria) 
• Gel Extraction Kit from Invitrogen (Invitrogen, Paisley, UK) 
• PCR Purification Kit from Invitrogen (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions. 
3.5.9  PCR  
PCR reactions are performed using the iCycler (system) (Bio-rad, stadt, staat), 
according to the manufacturer’s instructions. PCR enzymes used are purchased from 
Fermentas Life Sciences (St. Leon-Germany):   
• Pfu DNA Polymerase (2,5 u/µl) + 10x Pfu buffer + MgSO4 
• Dream Taq DNA Polymerase (5 u/µl) + 10x Dream Taq buffer + MgSO4 
3.5.9.1 Test – PCR small scale 
The PCR materials are thawed on ice.  
Preparation of mastermix (100 µl): 
• Polymerase (Pfu or Dream Taq)   1 µl 
• 10x Buffer (Pfu/Dream Taq) + MgSO4  10 µl 
• dNTPs (2mM)      10 µl 
• Primer 1 (50 pmol/µl)     1 µl   
• Primer 2 (50 pmol/µl)     1 µl 
• ddH2O       69 µl 
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Divide the mastermix into 3 labelled PCR eppis (each 23 µl) 
• Eppi 1   23 µl Mastermix + 2 µl ddH2O (negative control) 
• Eppi 2   23 µl Mastermix + 1 µl template DNA + 1 µl ddH2O 
• Eppi 3    23 µl Mastermix + 2 µl template DNA 
 
Put all 3 eppis into the PCR machine and start the PCR program  
• Step 1 – (1 cycle)    
  - Denaturation  - 95°C  3 min 
• Step 2 – (25 - 30 cycles)  
  - Denaturation - 95°C  30 sec 
  - Annealing  - 48°C-60°C 30 sec (dependent on primer Tm) 
  - Elongation   - 72°C  1 min / 1000 bp product 
• Step 3 – (1 cycle) 
  - Final elongation - 72°C  10 min 
3.5.9.2  PCR large scale 
The PCR materials are thawed on ice.  
Preparation of mastermix (300 µl): 
• Polymerase (Pfu or Dream Taq)   3 µl 
• 10x Buffer (Pfu/Dream Taq) + MgSO4  30 µl 
• dNTPs (2mM)      30 µl 
• Primer 1 (50 pmol/µl)     3 µl 
• Primer 2 (50 pmol/µl)     3 µl 
• ddH2O       207 µl 
 
For control divide the mastermix into 3 labelled PCR eppis (each 23 µl) 
• Eppi 1   23 µl Mastermix + 2 µl ddH2O (negative control) 
• Eppi 2   23 µl Mastermix + 1 µl template DNA + 1 µl ddH2O 
• Eppi 3    23 µl Mastermix + 2 µl template DNA 
 
For production divide the mastermix into 4 labelled PCR eppis (each 46 µl)  
• Eppi 4    46 µl Mastermix + 4 ml template DNA 
• Eppi 5-7  46 µl Mastermix + 2µl template DNA + 2µl ddH2O 
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Put all 7 eppis into the PCR machine and start the PCR program  
• Step 1 – (1 cycle)    
  - Denaturation  - 95°C  3 min 
• Step 2 – (25 - 30 cycles)  
  - Denaturation - 95°C  30 sec 
  - Annealing  - 48°C-60°C 30 sec (dependent on primer Tm) 
  - Elongation   - 72°C  1 min / 1000 bp product 
• Step 3 – (1 cycle) 
  - Final elongation - 72°C  10 min 
3.5.10 Primers 
Primers are received from Microsynth (Microsynth, Balgach, Swizerland) 
3.5.10.1  Cloning of pBGK-CGL 
Primer-set-1: 
Fwd Primer: [BglII] 
hCG[BglII]fwd: 5` AATAG ATC TCC AAG GAC CCG CTT  3´ 
Tm=54°C 
Rev Primer: [BstBI] 
hCG[BstBI]rev: 5` AATT TCG AAA GTT TTC CAT ACT GAT TGC 3´ 
Tm=52°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
 
Primer-set-2 (higher specificity): 
Fwd Primer-2: [BglII] 
hCG[BglII]fwd2: 5` AATAG ATC TCC AAG GAC CCG CTT CGG 3´ 
Tm=66°C 
Rev Primer-2: [BstBI] 
hCG[BstBI]rev2: 5` AATT TCG AAA GTT TTC CAT ACT GAT TGC CGC A 3´ 
Tm=66°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
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3.5.10.2  Cloning of pGLysivb-2x 
Fwd Primer: [NcoI] 
Eivb(NcoI)fwd: 5` AAT CCA TGG TCA GCC AAA CGT CTC TTC 3´ 
Tm=54°C 
Rev Primer: [XhoI] 
Eivb(XhoI)rev: 5` AAT CTC GAG TCA TTC GTG CCA TTC GAT T 3
3.5.10.3  Cloning of pGLMivb 
´ 
Tm=56°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
Fwd Primer: [XhoI] 
LacIq-XhoI-fwd: 5` ATA CTC GAG CAC CAT CGA ATG GTG CAA A 3´ 
Tm=56°C 
Rev Primer: [SbfI] 
LacIq-SbfI-rev: 5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3
3.5.10.4  Cloning of pGULMivb   
´ 
Tm=56°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
 Fwd Primer: [XhoI] 
LacIq-XhoI-fwd-2: 5` ATA CTC GAG CCG TCT GAA ATT CCG ACA CCA TCG AAT 
   G 3´ 
Tm = 64°C 
 Rev Primer: [SbfI] 
LacIq-SbfI-rev: 5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3´ 
Tm=56°C 
5’GCCGTCTGAA 3’ 10-Base-Pair sequence for Uptake of DNA  
….    Restriction sequence 
___    Binding region within the insert fragment 
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3.6  Protein gel electrophoresis and Western blot 
3.6.1  Protein sample preparation of bacterial culture (before lysis) 
The protein samples (1 ml) are diluted according to the OD600: 
 
OD600 value x 250 = Volume of 1x sample buffer 
 
The sample pellet is resuspended in the 1x sample buffer and it is mixed well. After 
that it is incubated at 99°C for 10 minutes. The protein sample can be stored at -20°C 
or used directly. Before loading on the gel the samples have to be spined down for 3 
minutes at maximum speed. The supernatants (~15 µl) are loaded on the gel.  
3.6.2  Protein sample preparation of lysed culture (after lysis) 
The protein samples (1 ml) are diluted according to the OD600: 
 
OD600 value (highest value before lysis) x 250 = Volume of 1x sample buffer 
 
The sample pellets of lysed cultures are resuspended always in the highest 
calculated volume of 1x sample buffer before lysis. Further treatment is done as for 
the samples before lysis.  
3.6.3  Protein sample preparation of lyophilized BG 
10 mg of lyophilized BG are weight and resuspended in 1 ml ddH2O. 200 µl of the BG 
suspension is mixed with 200 µl 1x NuPage sample buffer and incubated at 99°C for 
10 minutes. The suspension is spined down for 3 minutes at maximum speed. 100 µl 
of the supernatant are diluted with 400 µl 1x NuPage sample buffer. 2 µl, 5 µl 10 µl 
and 20 µl of the diluted sample are transferred in extra eppis and filled up with 1x 
NuPage sample buffer to a total volumen of 20 µl. The whole volume (20 µl) is loaded 
on the gel.  
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3.6.4  Protein sample preparation of positope (positive control) for 
quantification 
The positope (Invitrogen) with a molecular weight of 53 kDa is delivered as solution 
with a concentration of 25 ng/µl. A serial dilution (1:2) of positope is made:  
 
Standard Serial dilution – 1:2 Final concentration 
1. 40 µl of positope 500 ng/20µl 
2. 40 µl of positope + 40 µl of 1x sample buffer 250 ng/20µl 
3. 40 µl of 2. standard + 40 µl of 1x sample buffer 125 ng/20µl 
4. 40 µl of 3. standard + 40 µl of 1x sample buffer 62,5 ng/20µl 
5. 40 µl of 4. standard + 40 µl of 1x sample buffer 31,25 ng/20µl 
 
The standard samples are incubated at 99°C for 10 minutes and loaded on the gel 
(20 µl) without spin down.  
3.6.5  NuPAGE® Bis-Tris Electrophoresis system 
The proteins are separated using the NuPage® Bis-Tris Electrophoresis System 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructons. 
 
15 µl or 20 µl of prepared protein samples (see above) and 5 µl of molecular weight 
protein marker are loaded on gel, run at 180 Volt for 60 minutes.  
3.6.6  Western blot 
The protein transfer to nitrocellulose membrane is carried out using an xCell II Blot 
Module (Invitrogen, Paisley, UK) according to the manufacturer’s instructons. The 
blotting conditions are 30 Volt constant for blotting one gel or 60 Volt constant for 
blotting two gels for 60 minutes.  
Transfer efficiency and location of the protein marker is checked by staining with 
Ponceau S.  
Membrane blocking is carried out at 4°C overnight using Blocking Solution (1x Roti-
Block™, Carl Roth, Karlsruhe, Germany).  
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After washing 3 x 5 minutes and 1 x 10 minutes in TBST the membrane is incubated 
with the HRP-coupled first antibody for 1 hour. After antibody incubation the 
membrane is washed 3 x 5 minutes and 1 x 10 minutes in TBS. Membranes are 
developed with 3ml ECL-chemiluminescent reagent (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) according to manufacturer’s instructions.  
The Quantity One software (BioRad, Hercules, CA, USA) is used for the 
documentation and quantification. 
 
List of used antibodies: 
 
Direct 
detection 
antibodies  
Species type Uses Dilution Recognizes Source 
Anti-myc-
HRP 
mouse 
monoclonal IgG 
antibody 
WB 
1 to 
5.000 in 
TBS 
recombinant 
proteins 
containing the c-
myc epitope 
Invitrogen 
Anti-His(C-
term)-HRP 
mouse 
monoclonal IgG 
antibody 
WB 
1 to 
5.000 in 
TBS 
polyhistidine 
amino acid 
sequence at the 
C-terminus of a 
protein 
Invitrogen 
 
3.7  Growth, Expression and Lysis of Escherichia coli  
3.7.1  Growth study 
In the growth study the optimal growth temperature is determined for a bacterium. 
This experiment is carried out in 100 ml noseflasks with 25 ml of LBv. The growth of 
bacteria at different temperatures is observed. Inoculation is performed at OD600 ~ 
0.1 and growth observed for 240 minutes. At regular intervals OD, cfu and 
microscopy samples are taken, as seen from the following growth template. 
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1. Growth- Template: 
 
  
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain    
  1 2 3 4 5 6    
  28°C 28°C 36°C 36°C 42°C 42°C    
Min: Nr. 
25 ml LBv  25 ml LBv  25 ml LBv  25 ml LBv 25 ml LBv 25 ml LBv OD 
CFU 
each 
2x50
µl 
Micro
scope 
0 inoc              1-6     
30 A              1-6  1-6   
60 B              1-6  1-6  1,3,6 
120 C              1-6  1-6   
180 D              1-6  1-6   
240 E              1-6  1-6 1,3,6 
 
2. Growth- Template: 
 
  
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain 
Bacterium    
Strain    
  7 8 9 10 11 12    
  40°C 40°C 42°C 42°C 44°C 44°C    
Min: Nr. 
25 ml LBv  25 ml LBv  25 ml LBv  25 ml LBv 25 ml LBv 25 ml LBv OD 
CFU 
each 
2x50
µl 
Micro
scope 
0 inoc              1-6     
30 A              1-6  1-6   
60 B              1-6  1-6  1,3,6 
120 C              1-6  1-6   
180 D              1-6  1-6   
240 E              1-6  1-6 1,3,6 
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3.7.2 Lysis control study 
In the lysis control study one positive clone of bacterial strain with lysis plasmid is 
compared with a control strain with backbone plasmid in lysis behaviour.  
Experiments are carried out in the nose flasks with 25 ml of LBv and the 
corresponding antibiotics. For inoculation (OD600 ~ 0.1) the overnight culture of E. coli 
(lysis plasmid) and E. coli (backbone plasmid) are used. The nose flasks are 
incubated in a water bath at 36 ° C and 350 rpm. At OD600 ~ 0.4 lysis is induced by 
temperature upshift to 42 ° C and observed for the next 180 minutes. Uninduced 
samples are included as negative controls. During observation time OD, cfu, 
microscopy and western blot samples are taken (see Lysis control template). 
 
Lysis control template: 
    
Bacterium    
Strain 
(backbone 
plasmid) 
Bacterium    
Strain 
(backbone 
plasmid) 
Bacterium    
Strain     
(lysis 
plasmid) 
Bacterium    
Strain     
(lysis 
plasmid) 
    
    
1 2 3 4 
    
Time Min OD Nr. 
25 ml LBv + 
AB 
36°C 
  
25 ml LBv + 
AB 
36°C  
42°C at B 
25 ml LBv + 
AB 
36°C  
 
25 ml LBv + 
AB 
36°C  
42°C at B 
OD 
CFU 
1 x 
50µl 
1 x 
100µl 
WB 
1ml 
Micro
scope 
  
0,1-
0,15   
    
 1-4       
  
    
    
 1-4       
  
0,2 - 
0,25 A 
    
 1-4  1-4    1-4 
 
0 
0,3 - 
0,4 B 
    
 1-4  1-4  1-4   
 
20   C 
    
 1-4 2+4  2+4  2+4 
 
40   D 
    
 1-4 2+4  2+4  2+4 
 
60   E 
    
 1-4  1-4  1-4  1-4 
 
90   F 
    
 1-4 2+4  2+4  2+4 
 
120   G 
    
 1-4  1-4  1-4  1-4 
 
180   H 
    
 1-4  1-4  1-4  1-4 
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3.7.3  Growth- and Lysis- study in small scale 
Postive clones of bacterial strain with lysis plasmid (always in triplets) are checked for 
a Lysis consistency study to determine the clone with the best lysis behaviour. 
Experiments are carried out in the nose flasks with 25 ml of LBv and the 
corresponding antibiotics. For inoculation (OD600 ~ 0.1) the overnight culture of E. coli 
(lysis plasmid) is used. The nose flasks are incubated in a water bath at 36 ° C and 
350 rpm. At OD600 ~ 0.5 lysis is induced by temperature upshift to 42 ° C and 
observed for the next 120 minutes. During observation time OD, cfu, microscopy and 
western blot samples are taken (see Lysis template). 
 
Lysis- Template: 
 
   
Strain 
Plasmid 
Strain 
Plasmid 
Strain 
Plasmid   
 
 
   clone 1 clone 2 clone 3   
 
 
   1 2 3   
 
 
Min: OD Nr. 
25 ml LBv + AB 
36°C  
42°C at B 
25 ml LBv + AB 
36°C  
42°C at B 
25 ml LBv + AB 
36°C  
42°C at B 
OD 
CFU 
each 
4x50µl 
West. 
blot 
1ml 
Micros
cope 
  0,1-0,15         1-3  
 
  
            1-3     
  0,25 -0,3 A       1-3 1-3   1-3 
0 0,4 - 0,5 B       1-3 1-3 1-3   
10   C       1-3 1-3 1-3   
20   D       1-3 1-3 1-3   
40   E       1-3 1-3 1-3   
60   F       1-3 1-3 1-3  1-3 
90   G       1-3 1-3 1-3   
120   H       1-3 1-3 1-3   
 
3.7.3.1 Microskopie 
Bacterial Ghosts are distinguished from living bacteria. BG’s are much brighter than 
the living bacteria. 
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BG’s of E. coli K12 NM522 (pGLysivb): 
 
 
 
3.7.3.2  Determination of live cell counts, colony forming units = cfu 
The viable cell counts (CFU) are determined using a spiral plater (Don Whitley 
Scientific Limited, West Yorkshire, UK). Before plating the bacterial samples are 
serially diluted in saline (0,85% NaCl). For 1:10 dilutions 9 ml saline epprouvettes (9 
ml saline + 1 ml culture) and for 1:100 dilution 9,9 ml saline epprouvettes (9,9 ml 
saline + 0,1 ml culture) are used.  
Following dilutions according to the OD600 of growing and lysing cultures are given as 
a reference:  
Before lysis / Growth  After lysis – induction 
OD600 Dilution  OD600 Dilution 
0,05 – 0,5 104  1,5 – 1,0 105 
0,5 – 1,0 105  1,0 – 0,5 104 
1,0 – 2,0 106  0,5 – 0,2 103 
   0,2 – 0,01 102 
 
50 and/or 100 µl of the final dilutions are plated in logarithmic manner on count agar 
plates without any antibiotics. The plates are incubated at 28°C or 36°C over night 
and afterwords counted in the Synbiosis ProtoCOL Colony Counter machine (3.15, 
Synoptics Ltd., Cambridge, UK).  
BG 
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Cfu values are illustrated as a curve in a logarithmic manner together with the OD600 
values in one curve.  
3.7.4  Protein Expression- Study in small scale 
Expression study template: 
 
 
 
 
 
 
 
 
 
 
 
E.coli 
(pBGKA) 
 
negative contr. 
E.coli 
(pBAD/GIII/ 
Calmodulin) 
positive contr. 
E.coli 
(Expression 
plasmid) 
 
   1 2 3 West.
blot 
1ml 
 
Min: 
 
OD 
 
Nr. 
25 ml LBv  
36°C 
25 ml LBv  
36°C 
25 ml LBv  
36°C 
 0,1      
 0,2-0,3      
0 0,4-0,5 A    1-3 
30  B    1-3 
60  C    1-3 
 
Experiments are carried out in the nose flasks with 25 ml of LBv and the 
corresponding antibiotics. For  inoculation (OD600 ~ 0.1), the overnight cultures of E. 
coli (expression plasmid) are used.The nose flasks are incubated in a water bath at 
36 ° C and 350 rpm. The protein expression is induced at OD600 ~ 0.4-0.5 by addition 
of L-arabinose (final concentration 0.2%). Expression is carried out for the next 60 
minutes, during the entire study samples for western blot are taken (see expression 
study template). 
3.7.5  Expression- and Lysis- Study in small scale 
Experiments are carried out in nose flasks with 25 ml LBv and the corresponding 
antibiotic. For inoculation (OD600 ~ 0.1), overnight culture of E. coli (expression 
plasmid + lysis plasmid) are used. The nose flasks are incubated in a water bath at 
36 ° C and 350 rpm. The protein expression is induced at OD600 ~ 0.25 by addition of 
L-arabinose (final concentration 0,2%) and further incubated at 36 ° C. The lysis is 
induced at OD600 ~ 0.5 by temperature upshift to 42 ° C. Lysis is carried out for the 
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next 120 minutes. During the entire study OD, cfu, microscopy and Western blot 
samples are taken (see Expression and lysis-study template). 
 
Expression- and Lysis- Study template: 
   
Strain 
Plasmid 
Strain 
Plasmid 
Strain 
Plasmid    
   clone 1 clone 2 clone 3    
   1 2 3    
Min: OD Nr. 
25 ml LBv + AB 
36°C  
42°C at B 
25 ml LBv + AB 
36°C  
42°C at B 
25 ml LBv + AB 
36°C  
42°C at B 
OD 
CFU 
each 
4x50µl 
Microscope 
  0,1-0,15          1-3     
             1-3     
  0,25 -0,3 A        1-3  1-3  1-3 
0 0,4 - 0,5 B        1-3  1-3   
20   C        1-3  1-3   
40   D        1-3  1-3   
60   E        1-3  1-3   
90   F        1-3  1-3  1-3 
120   G        1-3  1-3   
150   H        1-3  1-3   
 
3.8 Fermentation in large scale 
For the production of BG in large scale 30 Liter fermentor – TECHFORS S (Infors AG, 
Bottmingen, Switzerland) is used (with a working volume of 20 Liter).  
3.8.1  Media preparation  
20 liters of LBv media are prepared and autoclaved (121°C) 18 hours before 
fermentation starts. During this time the IRIS program observs the pH, temperature, 
oxygen and flow. Before inoculation with the over night culture (~2 Liter) the sterility 
of the medium is controled by taking blank samples and plating them on count agar 
plates.  
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3.8.2  Overnight culture 
Working stocks of the production clone (-80°C) are thawn and used for the 
inoculation of 4 x 500 ml LBv with corresponding antibiotics. These four flasks are 
incubated overnight in water bath at 35°C.  
3.8.3  Fermentation process 
At the begining of fermentation, before the fermentor is inoculated with the overnight 
culture, corresponding antibiotics are added. During fermentation different 
parameters (temperature, oxygen flow, pO2, pH, rpm) are observed via the IRIS 
program. In regular intervals 50 ml samples are taken to determine OD600, cfu and for 
western blot and microscopy.  
The protein expression is induced by addition of L-Arabinose (Final concentration 
0,2%) at OD600 ~ 0,6.  
The lysis induction is induced 60 minuten after protein induction by temperature 
upshift to 44°C.  
3.8.4 Killing  
90 minuten after lysis induction the non-lysed bacteria are killed by the addition of 
double concentration of tetracyclin and streptomycin. The killing is performed for next 
60 minutes.      
3.8.5 Harvesting 
The BG’s are harvested using large and small tangential flow filtration (TFF) modules.  
3.8.6 Lyophilisation 
The 200 ml final products are spread to 10 lyophilization flasks (10 * 20 ml). The 
collection bottle is rinsed with some additional 10 ml of dH2O, the remainings are 
transferred to an eleventh lyophilization bottle. All lyophilization bottles are stored at - 
20°C, followed by storage at -80°C and lyophilized afterwards.  
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3.8.7 Calculation of Lysis efficacy and particles per mg 
The lysis efficiency is calculed using the following equation: 
 
Lysis efficacy [%] = [1 – (CFUlowest / CFUhighest )] x 100% 
 
 
The particles per mg are calculated using the following equation: 
 
Particles per mg [mg-1] = ( cfuhighest x volumetotal ) / weightlyophilized 
 
 
3.8.8 Sterility testing of the material 
The sterility testings are prepared in triplets. For each set a 10 mg of lyophilized BG 
are resuspended in 1,5 ml LBv. 100 µl and 200 µl of the resuspension are plated on 
LBv plates. 1 ml of the resuspension is mixed with 20 ml hand warm LB agar in an 
empty agar plate. 100 µl of the resuspension are added to a 5 ml LBv epprouvette. 
Plates and epprouvette are incubated over night at 36°C. On the next day 100 µl and 
200 µl of the liquid material are plated on LBv agar plates and incubated until the 
next day.  
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4 Results  
4.1 Bacterial ghosts as carrier of human chorionic 
gonadotropin – ß fused to the heat labile enterotoxin of 
E. coli (hCG-ß-LTB) 
 
The objective of my diploma thesis was the production of hCG-ß-LTB expression 
plasmids for BG - CV. 
4.1.1  Construction of hCG-ß-LTB expression plasmid for BG - CV 
4.1.1.1 Overview of the strategy 
Plasmid pDrive-hCG-ß-LTB was received from Dr. Talwar (Talwar research 
foundation, New Delhi, India). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: Linear map of pDrive-hCG-ß-LTB (Talwar research foundation, New Delhi, India) 
Contains target antigen hCG-ß-LTB between restriction sites of EcoRI and NotI.  
 
Plasmid pDrive hCG-ß-LTB (4530bp) contains the immunogenic sequence hCG-ß-
LTB (760bp) between restrictions sites of EcoRI and NotI (see Fig. 10).  
 
 
EcoRI NotI 
Target antigen 
hCGβ-LTB lac phage f 
Origin 
of 
Rep 
Ampicillin 
Antibiotic 
Resistance 
Kanamycin 
Antibiotic 
Resistance 
pMB1 
Origin of 
Replication 
Plac 
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HCG-ß-LTB is a fusionprotein and consists of: 
 
• hCGß (ß-subunit of human chorionic gonadotropin) sequence as antigen 
• LTB (heat labil toxin subunit B of E. coli) sequence as adjuvant 
• Linking-sequence (TCT AGA), a short sequence which connects hCGß- 
and  LTB-sequence 
 
The nucleotide sequence of hCG-ß-LTB is pictured in Tab. 1, the corresponding 
polypeptide sequence of hCG-ß and LTB is given in Tab. 2. 
 
 
 EcoRI 
GAA TTC TCC AAG GAC CCG CTT CGG CCA CGG TGC CGC CCC ATC AAT GCC ACC 
CTG GCT GTG GAG AAG GAG GGC TGC CCC GTG TGC ATC ACC GTC AAC ACC ACC 
ATC TGT GCC GGC TAC TGC CCC ACC ATG ACC CGC GTG CTG CAG GGG GTC CTG 
CCG GCC CTG CCT CAG GTG GTG TGC AAC TAC CGC GAT GTG CGC TTC GAG TCC 
ATC CGG CTC CCT GGC TGC CCG CGC GGC GTG AAC CCC GTG GTC TCC TAC GCC 
GTG GCT CTC AGC TGT CAA TGT GCA CTC TGC CGC CGC AGC ACC ACT GAC TGC 
GGG GGT CCC AAG GAC CAC CCC TTG ACC TGT GAT GAC CCC CGC TTC CAG GAC 
TCC TCT TCC TCA AAG GCC CCT CCC CCC AGC CTT CCA AGC CCA TCC CGA CTC CCG 
GGG CCC TCG GAC ACC CCG ATC CTC CCA CAA TCT AGA GGA GCT CCT CAG TCT ATT 
ACA GAA CTA TGT  TCG GAA TAT CAC AAC ACA CAA ATA TAT ACG ATA AAT GAC AAG 
ATA CTA TCA TAT ACG GAA TCG ATG GCA GGC AAA AGA GAA ATG GTT ATC ATT ACA 
TTT AAG AGC GGC GCA ACA TTT CAG GTC GAA GTC CCG GGC AGT CAA CAT ATA 
GAC TCC CAA AAA AAA GCC ATT GAA AGG ATG AAG GAC ACA TTA AGA ATC ACA 
TAT CTG ACC GAG ACC AAA ATT GAT AAA TTA TGT GTA TGG AAT AAA ACC CCC AAT 
TCA ATT GCG GCA ATC AGT ATG GAA AAC TAG GCG GCC GC 
                              Not I 
 
 
Tab. 1: Nucleotide sequence of hCG-ß-LTB gene. The green colored sequence represents the 
hCG-ß gene and the red colored sequence the LTB gene. The sequence was cloned into the cloning 
vector pDrive (Invitrogen, Paisley, UK) with restrictions sites marked as above. 
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Amino Acid Sequence of hCG-ß: 
 
SKDPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVV
CNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCD
DPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ 
 
BglII, Bsp119I 
Amino Acid Sequence of LTB:  
 
GAPQSITELCSEYHNTQIYTINDKILSYTESMAGKREMVIITFKSGATFQVEVPGSQH
IDSQKKAIERMKDTLRITYLTETKIDKLCVWNKTPNSIAAISMEN 
 
 
Tab. 2: Polypeptide sequence of hCGß and LTB gene 
 
The plasmid pDrive hCG-ß-LTB was transformed into E. coli K12 NM522 and 
glycerin stocks were produced.  Before using the plasmid for cloning it was checked 
via restriction enzyme digests. Following restriction enzymes were used:       
                        
--- no cut                   
NcoI, SacI, KpnI, EcoRI, XbaI 4530 bp one cut 
PstI 165 / 4365 bp two cuts 
 
PvuII 517 / 625 / 3388 bp three cuts 
 
All restriction enzymes cut as expected, except NcoI (see Fig. 11). 
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Fig. 11: Control-digest of pDrive-hCG-ß-LTB. 
Lane 1 – Fermentas GeneRuler 1kb DNA ladder; lane 2 – uncut pDrive-hCGß-LTB - correct; lane 3 – 
NcoI, single cutter, no cut; lane 4, 8, 9, 11– cut with SacI, KpnI, EcoRI, XbaI, expected size – 4530bp - 
correct; lane 5, 10 – cut with BglII, Bsp119I, non cutter - correct; lane 6 – cut with PstI, expected size – 
165/4365bp – correct (small fragment not visible); lane 7 – cut with PvuII, expected size – 
517/625/3388bp - correct. 
 
4.1.1.2  Cloning of pBGK-CGL plasmid  
Plasmid pBGK-CGL was cloned using pBGKA as a backbone for hCG-ß-LTB. For 
cloning strategy see Fig. 12. pBGK-CGL plasmid carries the pBAD promoter, the GIII 
signal sequence for transport of the fusion protein to the PPS and a Kanamycin 
resistance cassette. Further the plasmid carries the gene for the hCG-ß fused to the 
LTB (heat labil toxin subunit). 
 
 
 
 
 
 
 
 
1 0 0 0 0  
8 0 0 0  
6 0 0 0  
5 0 0 0  
4 0 0 0  
3 5 0 0  
3 0 0 0  
 
2 5 0 0  
 
2 0 0 0  
 
 
1 5 0 0  
 
 
 
1 0 0 0  
 
 
7 5 0  
 
 
 
5 0 0  
 
 
 
 
250 
 1         2        3        4        5       6        1       7        8        9      10      11       1 
                Uc         NcoI       SacI       BglII       PstI                    PvuII     KpnI    EcoRI    Bsp119I   XbaI 
 
 
1 0 0 0 0  
8 0 0 0  
6 0 0 0  
5 0 0 0  
4 0 0 0  
3 5 0 0  
3 0 0 0  
 
2 5 0 0  
 
2 0 0 0  
 
 
1 5 0 0  
 
 
 
 
1 0 0 0  
 
 
7 5 0  
 
 
 
5 0 0  
 
 
 
250 
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Fig. 12: Cloning strategy of pBGK-CGL. pBGKA is the backbone plasmid. pDrive-hCGß-LTB is the 
donor plasmid with target sequence hCG-ß-LTB. pBGK-CGL is the new plasmid containing a construct 
of GIII-hCG-ß-LTB-myc-His under control of arabinose inducible promotor pBAD.  
 
• 
The Insert (hCG-ß-LTB) was amplified via PCR, from plasmid pDrive-hCG-ß-LTB. 
Specific primers with restriction sites for BglII or BstBI were designed. The PCR 
product is shown in Fig. 13.  
 
Insert production  
Fwd Primer-2: [BglII] 
hCG[BglII]fwd2: 5` AATAG ATC TCC AAG GAC CCG CTT CGG 3´ 
Tm=66°C 
Rev. Primer-2: [BstBI] 
hCG[BstBI]rev2: 5` AATT TCG AAA GTT TTC CAT ACT GAT TGC CGC A 
araC 
3´ 
Tm=66°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
pBR322 Kanamycin     rrn 
 
Term. 
GIII-MCS-myc-His    PBAD 
 
Promotor 
BglII     BstBI 
pBGKA 
pMB1 Kanamycin Ampicillin phage f lac hCGβ-LTB 
Target sequence 
PCR – 751 bp 
BglII  BstBI 
 
 pDrive-hCG-ß-LTB 
Plac  
araC pBR322 Kanamycin rrn 
Ter 
GIII-hCGß-LTB-myc-His 
 
  PBAD 
 
Promotor 
BglII          BstBI pBGK-CGL 
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PCR was carried out according to standard protocol using: 
 
• Dream taq-Polymerase (5 u/µl) (Fermentas) 
• 10x dream-taq-buffer (+MgCl2)  
• dNTPs Mix (2mM) 
• annealing temperature calculated according to primers melting 
 temperature: 60°C 
• elongation time: 60 sec / cyclus, 72°C 
 
 
  
Fig. 13: hCG-ß-LTB PCR-product on 2% agarose. Lane 1 - 50bp DNA leader (fermentas); lane 2 - 
negative control for PCR; lane 3: hCG-ß-LTB PCR-product (undigested) - 761bp - correct. 
 
The PCR-product with the expected size of 761 bp, was eluted from 1% agarose gel 
using Xact DNA gel extraction Kit (Genexpress). Subsequently the product was 
purified a second time with Xact DNA gel extraction Kit (Genexpress) and double-
digested with BglII and BstBI = Bsp119I (conventional Enzymes from Fermentas). 
The digestion supplied a fragment with the size of 751bp which was further purified 
with Xact DNA gel extraction Kit (Genexpress), checked on a 1% agerose gel (see 
Fig. 14) and used for cloning into pBGK-CGL. 
 
hCGßLTB, 761bp 
1         2          3 
 
1000 
900 
800 
700 
 
600 
 
500 
 
400 
 
300 
250 
 
200 
150 
 
100 
 
50 
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Fig. 14: Digested and purified hCG-ß-LTB PCR-product (751 bp), on 1% agarose gel. Lane 1 - 
Fermentas GeneRuler 1kb DNA ladder; lane 2: hCG-ß-LTB - After digestion with BglII and Bsp119I 
and purification. 
   
• 
 
Plasmid pBGKA (Diploma thesis of Simone Schlacher, 2009) was used as backbone 
vector for cloning of pBGK-CGL. 
Plasmid pBGKA (4040bp, see Fig. 12) was checked via digestion by several 
restriction enzymes (see Fig. 15). Afterwards it was also double-digested with BglII 
and BstBI = Bsp119I (conventional enzymes from Fermentas). The digestion 
supplied two fragments 4012bp and 28bp. The bigger fragment was purified with 
Xact DNA gel extraction Kit from Genexpress (see Fig. 16). To avoid any religation of 
the vector, the 4012bp fragment was dephosphorylated with BAP (bacterial alkaline 
Phosphatase from Fermentas). 
 
Ligation of the vector fragment (4012bp) with the insert fragment (751bp) was 
performed at 4°C and over night, using T4 DNA ligase from NEB. After 
transformation into E. coli K12 C2988J, positive clones were identified by restriction 
analysis.  
 
Vector production 
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A.       B. 
 
Fig. 15: Control-digest of pBGKA. 
A: fast digest enzymes from Fermentas lane 1: Fermentas GeneRuler 1kb DNA ladder; lane2:  
BamHI 4040bp correct; lane3: SmaI 4040bp correct; lane4: SacI 4040bp correct; lane5: HindIII 
829/3211bp correct; lane6: XhoI 1384/2656bp correct. 
B: conventional enzymes from Fermentas lane1: Fermentas GeneRuler 1kb DNA ladder; lane2: 
uncut pBGKA; lane3: Bsp119I 4040bp correct; lane4: BglII 4040bp correct; lane 5: double-digest 
Bsp119I / BglII 4012/28bp correct (small fragment not visible) 
 
Fig. 16: Purified pBGKA-fragment (4012 bp), on 1% agarose gel. 
Lane 1 - Fermentas GeneRuler 1kb DNA ladder; lane 2 - pBGKA-fragment (4012bp) – After double 
digestion with BglII / Bsp119I and purification.  
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Positive clones were control-digested with ApaI (one cut in insert – hCG-ß-LTB, see 
Fig. 17) and with SmaI (cuts in insert – 2x and in vector – 1x, see Fig. 17). Digest of 
pBGK-CGL with ApaI or SmaI results theoretically in: 
 
ApaI  1 fragment  4763 bp 
SmaI   3 fragments  3340 / 1231 / 192 bp 
 
 
  
Fig. 17: Theoretical restriction pattern of pBGK-CGL. 
ApaI cuts 1x in insert (= hCG-ß-LTB); SmaI cuts 2x in insert and 1x in vector (= pBGKA).  
 
The control restriction analysis corresponded to the theoretical predicted size of 
pBGK-CGL (see Fig. 18). Positive clones were stored as glycerinstock and as 
midiprep. 
 
Fig. 18: Restriction analysis of correct pBGK-CGL clone. 
Lane 1: Fermentas GeneRuler 1kb DNA ladder; lane 2: pBGK-CGL uncut; lane 3: ApaI 4763bp correct; 
lane 4: SmaI 3340/1231/192bp correct.  
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4.1.1.3 Protein expression study of hCG-ß-LTB antigen from pBGK-CGL 
Via a protein expression study it is possible to test which pBGK-CGL clone shows the 
best expression of hCG-ß-LTB. In the same time it’s important to control that the 
antigen has no negative influence on the bacterial growth. 
The experiments were performed in 20 ml LBv with kanamycin with the following 
combinations: 
• E.coli K12 C2988J (pBGKA) as negative expression-control for WB (pBAD/gIII 
system without recombinant protein) 
• E.coli K12 C2988J (pBAD/GIII/calmodulin) as positive expression-control for 
WB (pBAD/gIII system with calmodulin as recombinant protein) 
• E.coli K12 C2988J (pBGK-CGL) – expression of hCGß-LTB by positive clones 
 
Optical density was messured at 600 nm. At OD600 ~ 0,3 the expression was induced 
by adding L-arabinose at a final concentration of 0,2%. The expression took 1h, 
during this time protein samples for expression-analyse were taken.  
.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: Western blot analysis of hCGß-LTB expression from E. coli K12 C2988J (pBGK-CGL) 
clone 2 and 3.  
--   E. coli K12 C2988J (pBGKA) 60 min; +   E. coli K12 C2988J (pBAD/GIII/calmodulin) 60 min; Clone 
2 is showing the best expression - a weak expresssion after 30 min and a stronger after 60 min of 
arabinose induction. At time point 0 min the hCGß-LTB expression was induced with L-arabinose.   
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The protein samples were analysed by western blot analysis. Expression of hCG-ß-
LTB was detected using Anti-myc-HRP antibodies (see Fig. 19), detecting the myc 
fused to hCG-ß-LTB. Expression of hCG-ß-LTB was detected for clone 2. A weak 
expression was seen after 30 min, a clear band detected after 60 min of arabinose 
induction. 
The expression of hCG-ß-LTB did not influence the bacterial growth negatively (data 
not shown). 
 
4.1.2 Expression and lysis study 
4.1.2.1  Expression and lysis study in E. coli K12 NM522 
E. coli K12 NM522 was co-transformed with the expression plasmid pBGK-CGL and 
the lysis plasmid pGLysivb. 
Positive clones were analysed by restriction analysis and used for the expression and 
lysis study.  
Noseflasks with 25 ml LBv including gentamycin and kanamycin were used to test 
the positive clones 1-4 of E. coli K12 NM522 (pBGK-CGL, pGLysivb). The hCG-ß-
LTB expression was induced with L-arabinose (final concentration of 0,2%) at OD600 
~ 0,2. The lysis induction was performed by temperature-upshift from 36°C to 42°C at 
OD600 ~ 0,5. During the experiment OD600 was measured, samples for cfu-
determination and protein-samples for western blot analysis were taken.  
 
As pictured below the bacterial growth was not affected by hCG-ß-LTB expresssion 
(see Fig. 20) and good lysis efficiency was reached (see Fig. 20). 
 
The protein samples were analysed by western blotting. Expression of hCG-ß-LTB 
was detected by anti-myc-HRP antibodies. As shown in Fig. 21, there is hCG-ß-LTB 
antigen expression and the maximum lies at 20 min after induction of lysis. After lysis 
induction concentration of the protein was decreasing.  
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Fig. 20: Growth and lysis curve of E. coli K12 NM522 (pBGK-CGL, pGLysivb) clone 1 - 4. 
Expression induction by addition of L-arabinose at OD600 ~ 0,2 (time point -55 min); Lysis induction – 
by temperature shift from 36°C to 42°C at OD600 ~ 0,5 (time point 0 min). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Western blot analysis of hCG-ß-LTB fusion protein from E. coli K12 NM522 (pBGK-CGL, 
pGLysivb) clone 1.  
The maximum of hCG-ß-LTB expression is 20 min after lysis induction, afterwards there is protein loss 
visible. Protein loss can have several reasons such as – uncorrect production of E-lysis tunnel or GIII 
transport to the PPS didn’t work or degradation of hCG-ß-LTB by high amount of proteases within the 
E.coli strain. Protein hCG-ß-LTB induction by L-arabinose at time point - 55 min; lysis induction by 
temperature shift from 36°C to 42°C at time point 0 min; + positive control of a former hCG-ß-LTB 
expression.   
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The protein loss can have several reasons such as: 
• Lysis process
• 
 – correct production of E-lysis tunnel didn’t work. One 
reason could be the nature of the bacterial strain or mechanical forces 
(physical conditions) which may have destroyed the cells. 
GIII-transport
• 
 to the periplasmic space didn’t work and cytoplasmic hCG-
ß-LTB is lost during lysis process 
Degradation of hCG-ß-LTB
 
The solution: 
 by high amount of proteases within the E. coli 
strain. 
• New bacterial strain – E. coli K12 W3110 – protease deficient (lon-)  
• Production in fermenter – other conditions 
• (New cloning strategy, with other vector and other transport system.) 
 
4.1.2.2  Expression and lysis study in E. coli K12 W3110 
E. coli K12 W3110 was co-transformed with the expression plasmid pBGK-CGL and 
the lysis plasmid pGLysivb. 
Positive clones were analysed by restriction analysis and used for the expression and 
lysis study.  
Noseflasks with 25 ml LBv complemented with gentamycin and kanamycin were 
used to test the positive clones of E. coli K12 W3110 (pBGK-CGL, pGLysivb). The 
hCG-ß-LTB expression was induced by addition of L-arabinose (final concentration of 
0.2%) at OD600 ~ 0.2. The lysis induction was carried out by temperature upshift from 
36 ° C to 42 ° C at OD600 ~ 0.5. During the experiment OD600 was measured, 
samples for cfu-determination and protein samples for western blot analysis were 
taken. 
The bacterial growth was not negatively influenced by the L-arabinose induction and 
lysis curves showed good lysis efficiency (see Fig. 22). 
Expression of hCG-ß-LTB-myc-His was detected by western blot analysis using anti-
myc-HRP antibodies. Expression of hCG-ß-LTB is visible after addition of L-
Arabinose and the protein concentration was not diminished after lysis induction (see 
Fig. 23). 
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Fig. 22: Growth and lysis curves of E. coli K12 W3110 (pBGK-CGL, pGLysivb) clone 1-4. 
Expression induction – by addition of L-arabinose at OD600 ~ 0,2; Lysis induction – by temperature 
upshift from 36°C to 42°C at OD600 ~ 0,5. 
  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23: Western blot analysis of hCG-ß-LTB expression from E. coli K12 W3110 (pBGK-CGL, 
pGLysivb) clone 1 and 2. 
hCG-ß-LTB expression before  (0 min) and after lysis (60 min; 90 min). After lysis induction there is no 
degradation of hCG-ß-LTB visible. Protein hCG-ß-LTB induction by L-arabinose at time point -60 min 
(not shown); Lysis induction by temperature upshift from 36°C to 42°C at time point 0 min; + positive 
control of a former hCG-ß-LTB expression.  
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4.1.3  Fermentation 
Fermentation processes were performed as described in material and methods. For 
fermentation the following bacterial strains were used: 
• E. coli K12 NM522 (pBGK-CGL, pGLysivb) - Clone 1 
• E. coli K12 W3110 (pBGK-CGL, pGLysivb) - Clone 2 
  
The fermentation approach was carried out in 22 liters LBv complemented with 
corresponding antibiotics - kanamycin (for the expression plasmid - pBGK-CGL) and 
gentamicin (for the lysis plasmid - pGLysivb). Protein expression was induced by 
addition of L-arabinose (final concentration of 0.2%). E-lysis induction was carried out 
by temperature shift from 35 ° C to 44 ° C 60 minutes after induction of protein 
expression. Killing of surviving bacteria was carried out 90 min after lysis induction by 
the addition of double concentration of tetracyclin and streptomycin (a standard 
method). The surviving bacteria can be killed also by a double dose of ß-Propiolacton 
(BPL). This new method of killing of remaining bacteria was in the test phase and 
therefore was not yet used. Harvesting and washing of BG were performed by 
tangential flow filtration (TFF). Lyophilized BG-material was controlled by sterility 
testings, western blotting analysis and quantification of the recombinant antigen. 
4.1.3.1  Fermentation of E. coli K12 NM522 (pBGK-CGL, pGLysivb) – clone 1 
Clone 1 of E. coli K12 NM522 (pBGK-CGL, pGLysivb), which has been tested before 
(see 4.1.2.1), was used for fermentation in 30 Liter fermenter. 
The bacterial strain was inoculated to an OD600 ~ 0,4. At OD600 ~ 0,6 hCG-ß-LTB 
expression was induced by addition of L-arabinose (a final concentration of 0.2%) 
(see Fig. 24). The bacterial growth was not negatively affected by the hCG-ß-LTB 
expression. 60 minutes after L-arabinose addition E-lysis was induced by a 
temperature shift from 35 ° C to 44 ° C (see Fig. 24). The E-lysis took another 90 
minutes and caused a cfu-drop from 108 to 104 (per ml). The surviving bacteria were 
killed by addition of double concentration of antibiotics (AB) for another 60 minutes 
(see Fig. 24).  
OD and cfu values are shown in Fig. 24.  
The lysis efficiency of this fermentation was 99,998%.      
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Fig. 24: Fermentation curve of E. coli K12 NM522 (pBGK-CGL, pGLysivb) – clone 1.   
hCG-ß-LTB protein induction by 0,2% L-arabinose at OD600 ~ 0,6; Lysis induction by temperature 
shift from 35°C to 44°C; Killing by streptamycin and tetracyclin double concentration (AB). 
Abbreviations:  -●- optical density;  -○- cfu. 
 
The IRIS software documents all important parameters during the fermentation such 
as stirrer, pH, oxygen, temperature and flow. The IRIS curve showing all documented 
parameters can be seen in Fig. 25. 
 
Fig. 25: IRIS curve of the fermentation of E. coli K12 NM522 (pBGK-CGL, pGLysivb) – clone 1 
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Main data of the fermentation process can be found also in the fermentation data 
sheet (Fig. 26): 
 
Pre-culture 
Volume: 4*500 ml Additives: Gent / Kan 
Medium type: LBv Other: - 
Date: 2009/02/19 Clone: c1 (12.12.2009, WS: 06.02.2009 by IHO) 
Starting time: 08:20 Strain: Escherichia coli NM522 
End time: 12:20 Plasmids: pGLysivb/pBGK-CGL 
ON culture OD: 2.251 / 0.541 Recombinant Protein Expression: HCGß-LTB 
Inoc. Volume: 1.60 l Expression Induction: 0.2% arabinose 
Medium: LBv Expression Induction Timepoint: B 
Antibiotics: Gent/Kan Lysis Induction: 44°C 
Temperature: 35°C Lysis Induction Timepoint: D 
Total Volume: ~ 22 L Killing: Strep, Tet double concentration (G) 
Acid: F.A.: 33 ml Volume harvested: 20 l 
Base: A.W.: 66 ml Harvested by: TFF (both steps + washing) 
Antifoam A: 25 ml OD seperator flow: < 0.000 
E-Blot: - Yield: 7890 mg 
R-Blot: OK (by IHO) Particles -/ mg: 1.05 x 109 
RT: - Sterility: OK (by AFA) 
Microscopy: okay Efficiency: 99.998 % 
 
Fig. 26: Fermentation data sheet of the fermentation of E. coli K12 NM522 (pBGK-CGL, 
pGLysivb) – clone 1   
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The bacterial ghosts were harvested by tangential flow filtration (TFF) and dried by 
lyophylisation. The fermentation yield was 7890 mg lyophilized material with 
calculated 1.05 x 109 particles per mg (see Fig. 26).  
 
Expression of hCG-ß-LTB-myc-His was detected by western blot analysis using anti-
His-HRP antibodies. Expression of hCG-ß-LTB (33,1 kDa) was seen after addition of 
L-arabinose. The concentration of the protein was not diminished after lysis induction 
(see Fig. 27) which is a proof of an intact periplasmic transport of hCG-ß-LTB.  
 
 
 
   
 
 
Fig. 27: Western blot analysis of hCG-ß-LTB expression from fermentation of E. coli K12 NM522 
(pBGK-CGL, pGLysivb) clone 1. hCG-ß-LTB protein is detectable 60 min after protein induction 
using anti-His-HRP antibodies and still present 150 min after lysis induction. Protein induction by L-
arabinose at time point -60 min (not shown); Lysis induction by temperature shift from 35°C to 44°C at 
time point 0 min; + positive control of a former hCG-ß-LTB expression. ON – over night culture E. coli 
K12 NM522 (pBGK-CGL, pGLysivb) clone 1 
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4.1.3.2 Fermentation of E. coli K12 W3110 (pBGK-CGL, pGLysivb) – clone 2 
Clone 2 of E. coli K12 W3110 (pBGK-CGL, pGLysivb), which has been tested before 
(see 4.1.2.2), was used for fermentation in 30 liter fermenter. 
 
The expression of hCG-ß-LTB protein was induced by addition of L-arabinose (final 
concentration of 0.2%) at OD600 ~ 0.6 (see Fig. 28). The bacterial growth was not 
negatively affected by the hCG-ß-LTB expression. 60 minutes after L-arabinose 
addition E- lysis was induced by a temperature shift from 35 ° C to 44 ° C (see Fig. 
28). The E-lysis took another 90 minutes and caused a cfu-drop from 108 to 104 (per 
ml). The surviving bacteria were killed again by addition of double concentration of 
antibiotics (AB) for another 60 minutes (see Fig. 28). OD and cfu values are shown in 
Fig. 28. 
 
The lysis efficiency of this fermentation was 99.995%.  
 
 
 
Fig. 28: Fermentation curves of E. coli K12 W3110 (pBGK-CGL, pGLysivb) – clone 2 
hCG-ß-LTB protein induction by 0,2% L-arabinose at OD600 ~ 0,6; Lysis induction by temperature shift 
from 35°C to 44°C; Killing by Streptomycin and Tetracyclin double concentration (AB). 
Abbreviations:  -●- optical density;  -○- cfu. 
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The IRIS curve showing all important fermentation parameters is shown in Fig. 29. 
 
 
 
Fig. 29: IRIS curve of the fermentation of E. coli K12 W3110 (pBGK-CGL, pGLysivb) – clone 2 
 
Main data of the fermentation process can be found also in the fermentation data 
sheet (Fig. 30): 
 
The bacterial ghosts were harvested by tangential flow filtration (TFF) and dried by 
lyophilisation. The fermentation yield was 9453 mg of lyophilized material with 
calculated 1.19 x 109 particles per mg (see Fig. 30). 
 
Expression of hCG-ß-LTB was detected by western blot analysis using anti-myc-HRP 
antibodies. Expression of hCG-ß-LTB (33,1 kDa) was seen after addition of L-
arabinose (see Fig. 31). The concentration of the protein was not decreasing after 
lysis induction which is a proof of an intact periplasmic transport of hCG-ß-LTB.  
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Pre-culture 
Volume: 4*500 ml Additives: Gent / Kan 
Medium type: LBv Other: - 
Date: 2009/02/13 Clone: c2 (28.01.2009, WS: 05.02.2009 by IHO) 
Starting time: 08:30 Strain: Escherichia coli W3110 
End time: 13:00 Plasmids: pGLysivb/pBGK-CGL 
ON culture OD: 2.280 / 0.561 Recombinant Protein Expression : HCGß-LTB 
Inoc. Volume: 0.78 l Expression Induction: 0.2% arabinose 
Medium: LBv Expression Induction Timepoint: C 
Antibiotics: Gent, Kan Lysis Induction: 44°C 
Temperature: 35°C Lysis Induction Timepoint: E 
Total Volume: ~ 22 L Killing: Strep, Tet double concentration (H)  
Acid: F.A.: 30.3 ml Volume harvested: 20 l 
Base: A.W.: 62.6 ml Harvested by: TFF (both steps + washing) 
Antifoam A: 36.8 ml OD seperator flow: < 0.000 
E-Blot: OK (by IHO) Yield: 9453 mg 
R-Blot: OK (by IHO) Particles -/ mg: 1.19 x 109 
RT: - Sterility: OK (by AFA) 
Microscopy: okay Efficiency: 99.995 % 
 
Fig. 30: Fermentation data sheet of the fermentation of E. coli K12 W3110 (pBGK-CGL, 
pGLysivb) – clone 2    
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Fig. 31: Western blot analysis of hCG-ß-LTB expression from fermentation of E. coli K12 W3110 
(pBGK-CGL, pGLysivb) clone 2. hCG-ß-LTB protein is detectable 30 min after protein induction 
using anti-His-HRP antibodies and still present 150 min after lysis induction. Protein induction by L-
arabinose at -60 min; Lysis induction by temperature shift from 35°C to 44°C at 0 min; + positive 
control of a former hCG-ß-LTB expression; ON – over night culture of E. coli K12 W3110 (pBGK-CGL, 
pGLysivb) clone 2.    
4.1.3.3 Quantification of recombinant hCG-ß-LTB from E. coli Ghosts produced 
by fermentation 
Recombinant protein hCG-ß-LTB of lyophilized bacterial ghosts was quantified using 
western blot analysis and the Quantity One program from BioRad (Hercules, CA, 
USA). The positope (Invitrogen) was used as standard for quantification.  
The positope with a molecular weight of 53 kDa is delivered with a concentration of a 
25 ng/µl. A serial dilution (1:2) of the positope was made and was loaded according 
to the following amounts for the standard curve calculation: 
 
• 500 ng   Standard 1 
• 250 ng   Standard 2 
• 125 ng   Standard 3 
• 62,5 ng  Standard 4 
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hCG-ß-LTB, 
 ~33,1 kDa 
 
positope, ~ 53 kDa 
  ___Standard [ng]                E. coli W3110       E. coli NM522      
  500    250    125    62,5   5µg    10µg  15µg   5µg   10µg  15µg 
 
The lyophilized hCG-ß-LTB bacterial ghosts were diluted as described in materials 
and methods and loaded on the gel: 
 
• 5 µg of BG’s  E. coli K12 NM522 or E. coli K12 W3110 
• 10 µg of BG’s  E. coli K12 NM522 or E. coli K12 W3110  
• 15 µg of BG’s   E. coli K12 NM522 or E. coli K12 W3110 
 
For the membrane development anti-myc-HRP antibodies were used (see Fig. 32). 
The quantification of the hCG-ß-LTB protein was performed using the QuantityOne 
Software of the ChemiDocXRS program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 32: Quantification western blot analysis of lyophilised hCG-ß-LTB bacterial ghosts from 
fermentation of E. coli K12 NM522 (pBGK-CGL, pGLysivb) clone 1 and E. coli K12 W3110 
(pBGK-CGL, pGLysivb) clone 2. As standard – positope (Invitrogen). 
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The quantificaton results are shown on the quantification curve in Fig. 33. 
Based on the standard curve the concentration of hCG-ß-LTB protein in BG of E. coli 
K12 NM522 and in BG of E. coli K12 W3110 was calculated: 
  
• 5 µg of BG’s E. coli K12 NM522  38,49 ng hCG-ß-LTB / µg BG 
• 10 µg of BG’s E. coli K12 NM522  40,52 ng hCG-ß-LTB / µg BG 
• 15 µg of BG’s  E. coli K12 NM522  54,51 ng hCG-ß-LTB / µg BG 
The resulting average was 44,51 ng hCG-ß-LTB / µg BG of E. coli K12 NM522. 
 
• 5 µg of BG’s E. coli K12 W3110  40,27 ng hCGßLTB / µg BG 
• 10 µg of BG’s E. coli K12 W3110  53,47 ng hCGßLTB / µg BG 
• 15 µg of BG’s  E. coli K12 W3110  55,52 ng hCGßLTB / µg BG 
The resulting average was 49,75 ng hCGßLTB / µg BG of E. coli K12 W3110. 
 
 
 
Fig. 33: Quantification curve of hCG-ß-LTB expressing BG’s of fermentations 
- E. coli K12 NM522 (pBGK-CGL, pGLysivb) clone 1 with resulting average of 44,51 ng hCG-ß-LTB / 
µg BG  
- E. coli K12 W3110 (pBGK-CGL, pGLysivb) clone 2 with resulting average of 49,75 ng hCG-ß-LTB / 
µg BG.  
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The lyophilized hCG-ß-LTB bacterial ghosts of E. coli K12 NM522 were sended to Dr. 
Talwar (Talwar Research Foundation, New Delhi, India) for animal trials. 
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4.2  Lysis plasmids   
4.2.1 Lysis plasmid – pGLysivb-2x 
Lysis plasmid pGLysivb-2x is a derivate of pGLysivb carrying a second temperature 
inducibel lysis cassette. The idea behind the construction of this plasmid was that two 
instead of one lysis cassettes should due to higher lysis efficiency as well to a more 
rapid lysis induction. 
4.2.1.1 Construction of lysis plasmid pGLysivb-2x 
The lysis cassette was amplified by PCR from pGLysivb, incorporating restriction 
sites for NcoI and XhoI. After cutting with these two enzymes the fragment (1380 bp) 
was ligated to the pGLysivb fragment (5788 bp) cutted with NcoI and XhoI (see Fig. 
34).  
 
For the PCR following primers were used:  
 
Eivb(NcoI)fwd: 5` AAT CCA TGG TCA GCC AAA CGT CTC TTC 3´ 
Tm=54°C 
Eivb(XhoI)rev: 5` AAT CTC GAG TCA TTC GTG CCA TTC GAT T 3
• Pfu - Polymerase (2,5 u/µl) from Fermentas 
´ 
Tm=56°C 
…. Restriction sequence 
___ Binding region within the insert fragment 
 
PCR was carried out according to standard protocol using: 
 
• 10x Pfu - buffer (+MgCl2) system 
 
After transformation of the ligation mix into E. coli K12 C2988J, positive clones were 
analysed by restriction digests and stored as glycerin stocks. 
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Fig. 34: Cloning strategy of pGLysivb-2x. pGLysivb is the backbone plasmid and donor plasmid for 
the lysis cassette. pGLysivb-2x contains two independent lysis cassettes which are under control of 
the λpR-cI857, each.  
4.2.1.2 Lysis control study of E. coli K12 C2988J (pGLysivb-2x) 
Experiments are carried out in the nose flasks with 25 ml of LBv and the 
corresponding antibiotics as described in material and methods. Two positive clones 
of E. coli K12 C2988J (pGLysivb-2x) were compared with E. coli K12 C2988J 
(pGLysivb) control in their lysis behaviour. Lysis induction was performed by 
temperature shift from 36°C to 42°C at OD600 ~ 0,3 - 0,4. Uninduced samples were 
included as negativ controls. 
Figure 35 shows the growth and lysis curves of two cultures of E. coli K12 C2988J 
(pGLysivb-2x) and of the positive control E. coli K12 C2988J (pGLysivb). 
E. coli K12 C2988J (pGLysivb-2x) clones showed a lower lysis efficiency compared 
to the positive control clone E. coli K12 C2988J (pGLysivb) (see Fig. 35 and Tab. 3). 
   Ori Eivb c1857 Eivb c1857   Mob. seq 
PRM   Pmut 
Gent 
NcoI XhoI 
PRM   Pmut 
pGLysivb-2x  
7168 bp 
   Ori Eivb c1857 Gentamycin 
PRM   Pmut 
 
  Mobil. seq 
pGLysivb 
6201 bp PCR 
 
1380bp 
EivbFwd 
 
(NcoI) 
EivbRev 
 
  (XhoI) 
PRM   Pmut 
 pGLysivb 
6201 bp 
Gentamycin   Mobil. seq c1857 Eivb    Ori 
NcoI     XhoI 
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Lysis efficiency is about 1 log lower than for the E. coli K12 C2988J (pGLysivb) 
control (see Tab. 3). 
 
 
 
 
Fig. 35: Growth (OD) and lysis (cfu) curves of E. coli K12 C2988J (pGLysivb) (1, 2); E. coli K12 
C2988J (pGLysivb-2x) clone 5 (3, 4); E. coli K12 C2988J (pGLysivb-2x) clone 7 (5, 6). The arrow 
indicates the time point of lysis induction by temperature shift from 36°C to 42°C for samples 2, 4, 6. 
Uninduced controls 1, 3, 5. E. coli K12 C2988J (pGLysivb-2x) clones show a lower lysis efficiency. 
 
 
cfu Highest cfu Lowest cfu Lysis efficiency 
E. coli K12 C2988J 
(pGLysivb) – positive control 
1,32 x 108 2,25 x 104 99,98% 
E. coli K12 C2988J 
(pGLysivb-2x) clone 5 
1,06 x 108 2,15 x 105 99,79% 
E. coli K12 C2988J 
(pGLysivb-2x) clone 7 
1,23 x 108 1,12 x 105 99,90% 
 
Tab. 3: Lysis efficiency of E. coli K12 C2988J (pGLysivb) and E. coli K12 C2988J (pGLysivb-2x) 
  
E. coli K12 C2988J (pGLysivb)              1, 2 
E. coli K12 C2988J (pGLysivb-2x) c5 -  3, 4 
E. coli K12 C2988J (pGLysivb-2x) c7 -  5, 6 
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4.2.2  Lysis plasmid – pGLMivb 
Lysis plasmid pGLMivb is a modification of pGLysivb, where the temperature 
inducible λpR-cI857 promotor repressor system was exchanged by a chemical 
inducible LacIq-Repressor-Ptac-Promotor system (lysis-induction with IPTG). 
pGLMivb was designed for bacteria with a growth optimum above 36°C.   
4.2.2.1 Construction of lysis plasmid pGLMivb 
The LacIq-Repressor-Ptac-Promotor cassette was amplified by PCR from pMal-p2x 
incorporating restriction sites for XhoI and SbfI. After cutting with these two enzymes 
the fragment (1487 bp) was ligated to the pGLysivb fragment (5193 bp) cutted with 
XhoI and SbfI (see Fig. 36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 36: Cloning strategy of lysis plasmid pGLMivb. pGLysivb is the backbone plasmid. pMal-p2x 
is the donor plasmid for the LacIq-repressor-Ptac-promoter cassette. pGLMivb contains the lysis gene 
Eivb under control of the LacIq-repressor-Ptac-promoter system.  
 
PRM  Pmut 
 
pGLysivb 
6201 bp 
Gentamycin  Mobil. seq c1857 Eivb Ori 
Origin 
XhoI  
  
SbfI 
Ptac 
 
LacIq Rev 
(SbfI) 
 
 
LacIq Fwd 
(XhoI) 
PCR, 1487 bp  
PLacIq 
 
pMal-p2x 
6721 bp 
  LacIq MBP Ampicillin pMB1 M13ori 
Ptac 
 
SbfI 
PLacIq 
 
pGLMivb 
6680 bp 
Gentamycin  Mobil. seq LacIq Eivb  Ori 
Origin 
XhoI 
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For the PCR following primers were used:  
 
LacIq-XhoI-fwd: 5` ATA CTC GAG CAC CAT CGA ATG GTG CAA A 3´ 
Tm=56°C 
 
LacIq-SbfI-rev: 5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3
• Pfu - Polymerase (2,5 u/µl) from Fermentas 
´ 
Tm=56°C 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
 
PCR was carried out according to standard protocol using: 
 
• 10x Pfu - buffer (+MgCl2) system 
 
After transformation of the ligation mix into E. coli K12 C2988J, positive clones were 
analysed by restriction digests and stored as glycerin stocks. 
4.2.2.2 Lysis control study of E. coli K12 C2988J (pGLMivb) 
Experiments are carried out in the nose flasks with 25 ml of LBv and the 
corresponding antibiotics as described in material and methods. One positive clone 
of E. coli K12 C2988J (pGLMivb) was compared with E. coli K12 C2988J 
(pBBR1MCS5) control in lysis behaviour. Plasmid pBBR1MCS5 (backbone of 
pGLysivb) does not carry the gene Eivb and therefore it does not undergo E-lysis.  
Lysis induction was performed by addition of IPTG (final concentration of 5mM) at 
OD600 ~ 0,3 - 0,4. Uninduced samples were included as negative controls.   
 
Fig. 37 shows the growth and lysis curves of E. coli K12 C2988J (pGLMivb) and the 
negative control E. coli K12 C2988J (pBBR1MCS5). The lysis of E. coli K12 C2988J 
(pGLMivb) is visible immediately after IPTG addition by decrease in cfu but the lysis 
efficiency is lower in contrast to E. coli K12 C2988J (pGLysivb) (see Tab. 4). One 
disadvantage is a rapid regeneration of non-lysed cells after endpoint of lysis.   
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Fig. 37: Growth (OD) and lysis (cfu) curves of E. coli K12 C2988J (pBBR1MCS5) (1, 2); E. coli 
K12 C2988J (pGLMivb) (3, 4). The arrow indicates the time point of lysis induction by IPTG addition 
(final concentration 5mM) for samples 2, 4. Uninduced controls – 1, 3. The lysis after IPTG addition is 
visible only by E. coli K12 C2988J (pGLMivb) – sample 4. 
 
cfu Highest cfu Lowest cfu Lysis efficiency 
E. coli K12 C2988J 
(pGLysivb) 
1,32 x 108 2,25 x 104 99,98% 
E. coli K12 C2988J 
(pGLMivb) 
1,05 x 108 2,49 x 106 97,62% 
 
Tab. 4: Lysis efficiency of E. coli K12 C2988J (pGLysivb) and E. coli K12 C2988J (pGLMivb) 
 
A western blot was performed to detect the protein Eivb expression using Strep-HRP. 
Fig. 38 shows the expression of Eivb protein and cytoplasmic BCCP. Only the IPTG-
induced E. coli K12 C2988J (pGLMivb) showed E-lysis which is also visible in Eivb 
exprcession after lysis induction. No Eivb expression was detected for the control E. 
coli K12 C2988J (pBBR1MCS5). 
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Fig. 38: Western blot showing Eivb protein and cytoplasmic BCCP from lysis control study of E. 
coli K12 C2988J (pGLMivb). 1 – E. coli K12 C2988J (pBBR1MCS5) without IPTG addition; 2 - E. coli 
K12 C2988J (pBBR1MCS5) with addition of IPTG at timepoint 0 min; 3 - E. coli K12 C2988J (pGLMivb) 
without lysis induction; 4 - E. coli K12 C2988J (pGLMivb) with lysis induction by IPTG at timepoint 0 
min – 20 min after lysis induction Eivb protein expression is visible; + positive control of a former Eivb 
expression.    
4.2.2.3 Lysis consistency study of E. coli K12 NM522 (pGLMivb) 
Bacterial strain E. coli K12 NM522 was used for the BG production.Therefore the 
lysis behavior of pGLMivb in E. coli K12 NM522 was studied in a consistency study. 9 
different clones of E. coli K12 NM522 (pGLMivb) were compared. The clone with the 
best lysis profil was selected for BG production by fermentation. Experiments are 
carried out in the nose flasks with 25 ml of LBv and the corresponding antibiotics as 
described in material and methods.  
 
E. coli K12 NM522 (pGLMivb) clone 8 showed the best lysis profil as shown in Fig. 
39 and Tab. 5. Immediately after IPTG addition a decrease in cfu occurred. Lysis end 
was reached already 40 min after IPTG addition. Further incubation resulted in 
regeneration of not lysed cells.  
 
A western blot was performed for qualitative analysis of Eivb protein and cytoplasmic 
BCCP. As shown in Fig. 40, all 9 clones of E. coli K12 NM522 (pGLMivb) show about 
the same expression level of Eivb protein. Concentration of cytoplasmic BCCP is 
very weakly as it is expelled during the lysis process. 
BCCP 
~22kDa 
 
 
Eivb 
~12,7kDa 
 
25,0 
18,4 
 
 
 
14,4 
  pBBR1MCS5                 pGLMivb  . 
 1         2          2          3         4         4          4          4          + 
kDa     120’      0’       120'     120’      0’       20’      40’      120’     
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Fig. 39: Growth (OD) and lysis (cfu) curve of E. coli K12 NM522 (pGLMivb) clone 7 – 9. The 
arrow indicates the time of lysis induction by IPTG addition. Clone 8 shows the best lysis profil. 
 
cfu Highest cfu Lowest cfu Lysis efficiency 
E. coli K12 NM522 (pGLysivb) – 
positive control 
7,87 x 107 6,50 x 103 99,99% 
E. coli K12 NM522 (pGLMivb) clone 1 2,66 x 108 4,72 x 105 99,82% 
E. coli K12 NM522 (pGLMivb) clone 2 2,61 x 108 4,53 x 105 99,82% 
E. coli K12 NM522 (pGLMivb) clone 3 1,93 x 108 6,63 x 105 99,65% 
E. coli K12 NM522 (pGLMivb) clone 4 1,23 x 108 1,67 x 105 99,86% 
E. coli K12 NM522 (pGLMivb) clone 5 1,87 x 108 5,54 x 105 99,70% 
E. coli K12 NM522 (pGLMivb) clone 6 2,40 x 108 3,49 x 105 99,85% 
E. coli K12 NM522 (pGLMivb) clone 7 1,66 x 108 3,00 x 105 99,81% 
E. coli K12 NM522 (pGLMivb) clone 8 1,67 x 108 1,61 x 105 99,90% 
E. coli K12 NM522 (pGLMivb) clone 9 1,31 x 108 1,44 x 105 99,89% 
 
Tab. 5: Lysis efficiency of E. coli K12 NM522 (pGLysivb) and E. coli K12 NM522 (pGLMivb) 
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Fig. 40: Western blot showing Eivb protein and cytoplasmic BCCP from lysis consistency 
study of E. coli K12 NM522 (pGLMivb). 1 – 9 = E. coli K12 NM522 (pGLMivb) clone 1 – 9, 60 min 
after lysis induction by IPTG. About the same Eivb expression level is visible in all clones. 
   
4.2.3  Lysis plasmid – pGULMivb 
Plasmid pGULMivb was designed for production of BGs of Neisseria species. 
Plasmid pGULMivb is a modification of pGLysivb where the temperature inducible 
λpR-cI857 promotor repressor system was exchanged by a chemical inducible LacIq-
Repressor-Ptac-Promotor system (lysis-induction with IPTG). Simultaneously the 
uptake-sequence of Neisseria (5'-GCCGTCTGAA-3 ') was introduced by PCR 
primers. This uptake sequence is necessary to transform a plasmid into Neisseria 
strains. 
4.2.3.1 Construction of lysis plasmid pGULMivb 
Plasmid pMal-p2x was used as template for amplification of the LacIq-Repressor-
Promoter-Ptac-cassette. Restriction sites for XhoI and SbfI and the uptake sequence 
of Neisseria (5’- GCCGTCTGAA- 3’) were introduced by PCR.  
BCCP 
~22 kDa 
 
Eivb  
~12,7 kDa 
 
-116,0 
 
-66,2 
 
 
-45,0 
 
-35,0 
 
 
 
-25,0 
-18,4 
 
 
 
-14,4 
kDa       1         2         3          4          5         6          7          8           9  
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Plasmid pGLysivb was digested with XhoI and SbfI to clone the digested PCR 
fragment using the compatible ends (see Fig. 41). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 41: Cloning strategy of lysis plasmid pGULMivb. pGLysivb is the backbone plasmid. pMal-p2x 
is the donor plasmid for the LacIq-repressor-Ptac-promoter cassette. pGULMivb contains the lysis 
gene Eivb under control of the LacIq-repressor-Ptac-promoter system. Additionally it contains the 
Neisseria sp.”uptake sequence” which was introduced by LacIq Fwd-2 primer.  
 
PCR was carried out according to standard protocol using: 
 
• Pfu - Polymerase (2,5 u/µl) from Fermentas 
• 10x Pfu - buffer (+MgCl2) system 
  
PRM  Pmut 
 
pGLysivb 
6201 bp 
Gentamycin  Mobil. seq c1857 Eivb Ori 
Origin 
XhoI  
  
SbfI 
 
Ptac 
 
LacIq Rev 
(SbfI) 
 
 
LacIq Fwd-2 
(XhoI + 
uptake seq.) 
PCR, 1503 bp  
PLacIq 
 
pMal-p2x 
6721 bp 
  LacIq MBP Ampicillin pMB1 M13ori 
Ptac 
 
SbfI 
PLacIq 
 
pGULMivb 
6696 bp 
Gentamycin  Mobil. seq LacIq Eivb  Ori 
Origin 
XhoI – GCCGTCTGAA –  
 (= uptake seq.) 
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For the PCR following primers were used:  
 
LacIq-XhoI-fwd2:  
5` ATA CTC GAG CCG TCT GAA ATT CCG ACA CCA TCG AAT G 3´ 
Tm = 64°C 
LacIq-SbfI-rev: 5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3
 
 
´ 
Tm=56°C 
 
5’GCCGTCTGAA 3’ -10-Base-Pair sequence for Uptake of DNA  
….    Restriction sequence 
___    Binding region within the insert fragment 
 
 After transformation of the ligation mix into E. coli K12 C2988J, positive clones were 
analysed by restriction digests (see Fig. 42) and stored as glycerin stocks. 
 
 
Fig. 42: Control-digest of pGULMivb. Lane 1: Fermentas GeneRuler 1kb DNA ladder; lane 2: SacI 
6696bp correct; lane 3: PvuII 2968/1352/1281/1002/93bp (small fragment not visible) correct; lane 4: 
MluI 6696bp correct; lane 5: EcoRV 4620/2076bp correct; lane 6: ApaI 6032/664bp correct.   
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4.2.3.2 Lysis consistency study of E. coli K12 NM522 (pGULMivb) 
Bacterial strain E. coli K12 NM522 was used for the BG production.Therefore the 
lysis behavior of pGULMivb in E. coli K12 NM522 was studied in a consistency study. 
6 different clones of E. coli K12 NM522 (pGULMivb) were compared. The clone with 
the best lysis profil was selected for BG production by fermentation. Experiments are 
carried out in the nose flasks with 25 ml of LBv and the corresponding antibiotics as 
described in material and methods.  
 
E. coli K12 NM522 (pGULMivb) clone 6 showed the best lysis profil as shown in Fig. 
43 and Tab. 6. Immediately after IPTG addition a decrease in cfu occurred. Lysis end 
was reached already 40 min after IPTG addition. Further incubation resulted in 
regeneration of not lysed cells.  
 
 
 
Fig. 43: Growth (OD) and lysis (cfu) curve of E. coli K12 NM522 (pGULMivb) clone 4 – 6. The 
arrow indicates the time of lysis induction by IPTG addition. Clone 6 shows the best lysis profil. 
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cfu Highest cfu Lowest cfu Lysis efficiency 
E. coli K12 NM522 (pGLysivb) – 
positive control 
7,87 x 107 6,50 x 103 99,99% 
E.coli K12 NM522 (pGULMivb) clone1 6,66 x 107 8,19 x 105 98,77% 
E.coli K12 NM522 (pGULMivb) clone2 7,84 x 107 1,09 x 106 98,61% 
E.coli K12 NM522 (pGULMivb) clone3 1,41 x 108 7,73 x 105 99,45% 
E.coli K12 NM522 (pGULMivb) clone4 1,97 x 108 1,84 x 106 99,07% 
E.coli K12 NM522 (pGULMivb) clone5 1,62 x 108 1,35 x 107 91,67% 
E.coli K12 NM522 (pGULMivb) clone6 1,49 x 108 7,02 x 105 99,53% 
 
Tab. 6: Lysis efficiency of E. coli K12 NM522 (pGLysivb) and E. coli K12 NM522 (pGULMivb) 
 
A western blot was performed for qualitative analysis of Eivb protein and cytoplasmic 
BCCP. As shown in Fig. 44, all 6 clones of E. coli K12 NM522 (pGULMivb) showed 
the expression of Eivb protein. Concentration of cytoplasmic BCCP is weakly as it is 
expelled during the lysis process.                         
                     
 
 
                       
 
Fig. 44: Western blot showing Eivb protein and cytoplasmic BCCP from lysis consistency 
study of E. coli K12 NM522 (pGULMivb). 1 – 6 = E. coli K12 NM522 (pGULMivb) clone 1 – 6, 60 min 
after lysis induction by IPTG. Eivb expression is visible in all clones. 
   
Transformation into Neisseria sp. was not analysed yet.
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5 Discussion 
5.1 Bacterial ghosts as carrier of hCG-ß-LTB 
The aim of this study was the production of an immunocontraceptive vaccine on the 
basis of the bacterial ghost system. Former studies of hCG vaccination in women 
passed the Phase II of clinical trials but generates protective threshold titers in only 
60-80% of women. A birth control vaccine has to be effective in more than 90-95% of 
recipients [2]. Bacterial ghosts function as carrier of foreign antigens and/or as 
adjuvants. Therefore the bacterial ghost system provides a good possibility to 
increase the effectiveness.  
 
The first part of this study was the construction of an expression plasmid, pBGK-CGL, 
which contains the target sequence of hCG-ß-LTB (developed by Dr.Talvar). The 
new plasmid, pBGK-CGL, is based on pBGKA [14] (see Fig. 43).  
 
 
 
Fig. 43: Linear map of pBGKA.  
 
Therefore pBGK-CGL shows the main properties of the pBAD/GIII system: 
 
• tightly regulated expression of target protein through the L-arabinose 
induced promoter 
• GIII transport system of target protein to the periplasmic space 
• Myc-His construct for the detection via anti-Myc and anti-His antibodies  
 
The cloned target gene hCG-ß-LTB was inserted downstream of the GIII gene 
resulting in a GIII-hCG-ß-LTB-Myc-His fusion protein. GIII as a signal sequence for 
the targeted transport in the periplasmic space is cleaved by its passage through the 
inner membrane.  
PBAD GIII-MCS-myc-His rrn 
Ter 
Kanamycin pBR322 araC 
 BglII    BstBI pBGKA 
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The function of the new plasmid pBGK-CGL, which was transformed in E. coli K12 
C2988J, was carried out by expression study.  The expression of the hCG-ß-LTB-
Myc-His fusion protein was detected by western blot analysis (see Fig. 19). 
 
E. coli K12 NM522 was cotransformed with expression plasmid pBGK-CGL and lysis 
plasmid pGLysivb. The expression and lysis study of E. coli K12 NM522 (pBGK-CGL, 
pGLysivb) showed that hCG-ß-LTB did not influence the bacterial growth (see Fig. 
20).  
The E-mediated lysis is induced by a shift of temperature from 35-42°C.Fig. 20 
showed good lysis efficiency. The expression of the hCG-ß-LTB-myc-His fusion 
protein was detected by western blot analysis (see Fig. 21). Results of western blot 
analysis also showed 20 minutes after lysis induction there was an unexpected 
decrease of protein concentration hCG-ß-LTB. There could be several reasons for 
that:  
 
• Bacterial strain 
• Wrong fermentation conditions (mechanical forces, impaired lysis tunnel 
formation)  
• Impaired GIII transport  
 
Possible solutions: 
 
• New bacterial strain (E. coli K12 W3110 which is protease deficient) 
• New fermentation conditions (large-scale fermentation) 
• New transporter system (new cloning strategy)  
 
Therefore E. coli K12 W3110 was cotransformed with expression plasmid pBGK-CGL 
and lysis plasmid pGLysivb. The expression and lysis study of E. coli K12 W3110 
(pBGK-CGL, pGLysivb) showed that hCG-ß-LTB did not influence the bacterial 
growth (see Fig. 22).  
The E-mediated lysis is induced by a shift of temperature from 35-42°C. Fig. 22 
showed good lysis efficiency. The expression of the hCG-ß-LTB-myc-His fusion 
protein was detected by western blot analysis (see Fig. 23), which showed no protein 
loss after lysis induction.  
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The best clones of the tested bacterial strains E. coli K12 W3110 (pBGK-CGL, 
pGLysivb) and E. coli K12 NM522 (pBGK-CGL, pGLysivb) were used for the large-
scale fermentation in the 30 liter fermeter. Under these conditions also E. coli K12 
NM522 showed no protein loss after lysis induction (see Fig. 27). 
  
Fermentation of E. coli K12 NM522 (pBGK-CGL, pGLysivb) clone 1 
Lysis efficiency 99,998 %  
Yield 7890 mg 
Particles - / mg 1,05 x 109 
ng hCGß-LTB / µg BG 44,51 ng / µg BG 
  
Fermentation of E. coli K12 W3110 (pBGK-CGL, pGLysivb) clone 2 
Lysis efficiency 99,995 % 
Yield 9453 mg 
Particles - / mg 1,19 x 109 
ng hCGß-LTB / µg BG 49, 75 ng / µg BG 
 
Tab. 6: Results of large scale fermentations – lysis efficiency, yield, particles / mg, average of ng 
hCG-ß-LTB / µg BG.  
 
As shown in Tab. 6 both large scale fermentations indicate similar results. 
Fermentation of E. coli K12 W3110 exhibits greater yield and higher concentrations 
of hCG-ß-LTB target protein. Lyophilized bacterial ghosts of both large-scale 
fermentations have been sent to Dr. Talwar (Talwar Research Foundation, New Delhi, 
India) for further immunological approaches.  
Following immunological studies should show if those hCG-ß-BG-vaccine, produced 
in this work, due to a better efficiency compared to the previous hCG-ß-vaccines. 
5.2  Lysis plasmids 
 
Lysis plasmids are essential for the production of bacterial ghosts. The efficiency of 
lysis mainly depends on the promoter that controls expression of lysis gene E but can 
also be influenced by other factors like plasmid size, other genes (eg. resistance 
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genes) and the bacterial system in which you will induce E-mediated lysis. Because 
of that all lysis plasmids have to be tested after construction.  
 
In this work three lysis plasmids have been constructed:  
 
• pGLysivb-2x 
• pGLMivb 
• pGULMivb 
 
All three plasmids are derived from pGLysivb.  
 
In pGLysivb-2x the expression of the two lysis genes E is controlled by a temperature 
inducible λpR-cI857 promoter-repressor system. The idea behind the construction of 
this plasmid was that two instead of one lysis cassettes should due to higher lysis 
efficiency as well to a more rapid lysis induction. Unfortunately this was not the case, 
in contrast the new lysis plasmid showed poor lysis and lysis efficiency compared to 
pGLysivb (see Fig. 35, Tab. 3). One explanation for these results could be the mutual 
inhibition of the two E-lysis cassettes.  
 
In case of pGLMivb instead of temperature inducible promoter-repressor system, a 
Lac-Iq-repressor-Ptac-promoter system was used. Some bacteria show optimal 
growth by temperatures above 36°C. So a temperature inducible system, which is 
sensitive to temperature up to 36°C, would not be useful. The pGLMivb showed good 
lysis efficiency and a fast lysis, but also a rapid regeneration of non-lysed bacteria 
after the end-point of lysis (see Fig. 39, 40; Tab. 5). 
 
The construction of pGULMivb was based on nearly the same principle as that of 
pGLMivb. The expression of lysis gene E was controlled by the Lac-Iq-repressor-
Ptac-promoter system, since it is known that the optimal growth of Neisseria sp. is at 
higher temperatures. Additionally an uptake sequence was introduced via primers 
(see Fig. 41) to enable the admission of the pGULMivb during transformation.  
The cloning strategy, cloning and lysis analysis was performed in this work. The 
pGULMivb showed nearly the same results like pGLMivb. The pGULMivb showed 
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also good lysis efficiency, fast lysis and a rapid regeneration of non-lysed bacteria 
after the end-point of lysis (see Fig. 43, 44; Tab. 6). 
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7 Appendix 
 
Overview 
 
Backbone plasmids: 
 
Plasmid  Expression 
cassettes 
Resistance Origin Size 
[Kb] 
References 
pBGKA  PBAD-gIII-MCS-
myc-His 
Kanamycin pBR322 4,04 [14] 
pDrive-hCG-
ß-LTB 
Plac-hCG-ß-LTB Kanamycin 
/ Ampicillin 
pMB1 4,53 [51] 
pMal-p2x LacIq-Ptac-malE Ampicillin pMB1 6,721 New 
England 
Biolabs  
 
Expression plasmids: 
 
Plasmid  Expression 
cassettes 
Resistance Origin Size 
[Kb] 
References 
pBGK-CGL PBAD-gIII-MCS-
hCG-ß-LTB-myc-
His 
Kanamycin pBR322 4,763 this work 
 
Lysis plasmids:  
 
Plasmid  Expression 
cassettes 
Resistance Origin Size 
[Kb] 
References 
pGLysivb cI857- λPRmut -Eivb Gentamycin Rep 6,201 [32] 
pGLysivb-2x 
(B) 
cI857- λPRmut -Eivb   
/  
cI857- λPRmut -Eivb 
Gentamycin Rep 7,168 this work 
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pGLysivb-2x 
(A) 
cI857- λPRmut -Eivb 
/  
cI857- λPRmut -Eivb 
Gentamycin Rep 7,274 this work  
(not 
working) 
pGLMivb LacIq-Ptac-Eivb Gentamycin Rep 6,68 this work 
pGULMivb Uptake seq. / 
LacIq-Ptac-Eivb 
Gentamycin Rep 6,696 this work 
pGELys cI857- λPRmut -Eivb Gentamycin Rep 5,06 [10] 
pGES cI857- λPRmut -Eivb Gentamycin Rep 4,482 this work 
(not 
working) 
pGLNIc cI857- λPRmut -Eivb 
/  
LacIq-Plac-Snuc 
Gentamycin Rep 8,309 [52] 
pGLNIs cI857- λPRmut -Eivb 
/  
LacIq-Plac-Snuc 
Gentamycin Rep 7,168 this work 
(not 
working) 
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Construction of plasmid pBGK-CGL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer:  
 
hCG[BglII]fwd2: 5` AATAG ATC TCC AAG GAC CCG CTT CGG 3´ 
 
hCG[BstBI]rev2: 5` AATT TCG AAA GTT TTC CAT ACT GAT TGC CGC A 
 
3´ 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
 
 
hCGß-LTB 
BstBI BglII 
751 bp 
PBAD 
GIII-MCS-myc-His rrn 
Terminator 
Kanamycin pBR322 araC 
BglII  
pBGKA 
(4,04 kb) 
BstBI 
GIII-MCS-hCGß-LTB-myc-His rrn 
Ter 
Kanamycin pBR322 araC 
BstBI 
PBAD 
BglII  
pBGK-CGL 
(4,763 kb) 
  hCGβ-LTB lac phage f Ampicillin Kanamycin pMB1 
pDrive-hCG-ß-LTB 
(4,530 kb) 
hCG[BstBI]rev2 
hCG[BglII]fwd2 
Plac 
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Construction of plasmid pGLysivb-2x   (B - strategy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer:  
 
Eivb(NcoI)fwd: 5` AAT CCA TGG TCA GCC AAA CGT CTC TTC 3´ 
 
Eivb(XhoI)rev: 5` AAT CTC GAG TCA TTC GTG CCA TTC GAT T 3´ 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
PRM   Pmut 
 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
pGLysivb 
(6,201 kb) 
Eivb(NcoI)fwd 
Eivb(XhoI)rev 
PRM   Pmut 
Gen
 
  Mobil. seq c1857 Eivb  Rep 
NcoI 
Eivb 
XhoI 
c1857 
PRM   Pmut 
pGLysivb-2x 
(B)  
(7,168 kb) 
XhoI NcoI 
PRM   Pmut 
 
c1857 Eivb 
1380 bp 
PRM   Pmut 
 
pGLysivb 
(6,201 kb) 
Gentamycin   Mobil. seq c1857 Eivb  Rep 
NcoI  
XhoI  
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Construction of plasmid pGLMivb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer:  
 
LacIq-XhoI-fwd: 5` ATA CTC GAG CAC CAT CGA ATG GTG CAA A 3´ 
 
LacIq-SbfI-rev: 5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3´ 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
 
Ptac 
 
LacIq-SbfI-rev 
 
 
LacIq-XhoI-fwd 
 
PLacIq 
 
pMal-p2x 
(6,721 kb) 
  LacIq MBP Ampicillin pMB1 M13ori 
1487 bp  
SbfI XhoI 
Ptac 
 
PLacIq 
 
  LacIq 
Ptac 
 
SbfI 
PLacIq 
 
pGLMivb 
(6,680 kb) 
Gentamycin  Mobil. seq LacIq Eivb  Rep 
XhoI 
PRM  Pmut 
 
pGLysivb 
(6,201 kb) 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
XhoI  
  
SbfI 
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Construction of plasmid pGULMivb 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer:  
 
LacIq-XhoI-fwd-2: 
5` ATA CTC GAG CCG TCT GAA ATT CCG ACA CCA TCG AAT G 3´ 
 
LacIq-SbfI-rev:  
5` ATA CCT GCA GGA CTG GCT GTT TCC TGT 3´ 
 
5’GCCGTCTGAA 3’ -10-Base-Pair sequence for Uptake of DNA  
….    Restriction sequence 
___    Binding region within the insert fragment 
Ptac 
 
LacIq-SbfI-rev 
 
 
LacIq-XhoI-fwd-2 
 
PLacIq 
 
pMal-p2x 
(6,721 kb) 
  LacIq MBP Ampicillin pMB1 M13ori 
1503 bp  
SbfI XhoI-GCCGTCTGAA –  
         (= uptake seq.) 
 
Ptac 
 
PLacIq 
 
  LacIq 
PRM  Pmut 
 
pGLysivb 
(6,201 kb) 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
XhoI  
  
SbfI 
Ptac 
 
SbfI 
PLacIq 
 
pGULMivb 
(6,696 kb) 
Gentamycin  Mobil. seq LacIq Eivb  Rep 
XhoI-GCCGTCTGAA –  
         (= uptake seq.) 
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Construction of plasmid pGLysivb-2x   (A – strategy, not working) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer:  
 
Eivb(PvuI)fwd: 5` AATT CGA TCG TCA GCC AAA CGT CTC TTC 3´ 
 
Eivb(AgeI)rev: 5` AAT ACC GGT TCA TTC GTG CCA TTC GAT T 3´ 
AgeI = BshTI 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
PRM   Pmut 
 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
pGLysivb 
(6,201 kb) 
Eivb(PvuI)fwd 
Eivb(BshTI)rev 
PRM   Pmut 
Gent   Mobil. seq c1857 Eivb  Rep 
BshTI 
Eivb 
PvuI 
c1857 
PRM   Pmut 
pGLysivb-2x 
(A) 
(7,274 kb) 
BshTI PvuI 
PRM   Pmut 
 
c1857 Eivb 
1377 bp 
PRM   Pmut 
 
pGLysivb 
(6,201 kb) 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
PvuI  
BshTI  
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Construction of plasmid pGES   (not working) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid pGELys is used as insert for cloning 
Insert pGELys [5060bp]  KasI / BsrGI 
4394bp / 666bp 
 
 
 
PRM   Pmut 
 
pGELys 
(5,060 kb) 
Gentamycin c1857 Eivb  Rep 
KasI  BsrGI  
666 bp  
BsrGI KasI 
Gentamycin 
PRM   Pmut 
 
pGLysivb 
(6,201 kb) 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
KasI  Acc65I  
PRM   Pmut 
 
pGES 
(4,482 kb) 
Gentamycin c1857 Eivb  Rep 
KasI  RsaI  
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Construction of plasmid pGLNIs   (not working) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR primer: 
 
Gent (SnaI)Fwd: 5` ATA GTA TAC TTA GGT GGC GGT ACT TGG GTC3´ 
[SnaI=BstZ17I] 
 
Gent (Cfr9I)Rev: 5` ATA CCC GGG CTG CAG GAA TTC GA 3´ 
[Cfr9I=SmaI] 
 
…. Restriction sequence 
___ Binding region within the insert fragment 
PRM   Pmut 
 
Gentamycin c1857 Eivb Rep 
pGELys 
(5,060 kb) 
Gent(SnaI)fwd 
Gent(Cfr9I)rev 
Cfr9I SnaI 
1252 bp 
Gentamycin 
PRM   Pmut 
 
Gentamycin c1857 Eivb  Rep 
pGLNIs 
(7,168 kb) 
LacIq Snuc 
SnaI Cfr9I 
PRM   Pmut 
 
Gentamycin  Mobil. seq c1857 Eivb  Rep 
pGLNIc 
(8,309 kb) 
SnaI 
LacIq Snuc 
Cfr9I 
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